https://trial.medpath.com/news/200b8a1e846aedc1/intas-pharmaceuticals-gets-cdsco-panel-nod-to-study-r-hfsh-solution-for-injection 2024-11-10T18:43:12+00:00 weekly 0.7 https://trial.medpath.com/news/a40909e7ab0900cc/virus-therapy-gets-orphan-drug-designation-for-glioma-treatment-oncology-nursing-news 2024-11-10T18:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/eed9fe4076094ca5/serial-killing-cell-therapy-from-autolus-lands-fda-approval-in-blood-cancer 2024-11-10T17:32:45+00:00 weekly 0.7 https://trial.medpath.com/news/de48039a17a27171/j-j-bids-to-add-smouldering-myeloma-to-darzalex-label-pharmaphorum 2024-11-10T17:28:14+00:00 weekly 0.7 https://trial.medpath.com/news/37f795f379b5052c/antio-cel-shows-promising-results-in-relapsed-refractory-multiple-myeloma 2024-11-10T17:12:43+00:00 weekly 0.7 https://trial.medpath.com/news/904d16763a06abb7/weight-loss-pill-passes-important-safety-trial-new-atlas 2024-11-10T16:43:40+00:00 weekly 0.7 https://trial.medpath.com/news/47780fc876a3b89d/earnings-call-relmada-therapeutics-reports-q3-financials-focuses-on-rel-1017 2024-11-10T16:33:17+00:00 weekly 0.7 https://trial.medpath.com/news/0d45618c9a25dc0d/nktr-255-shows-promise-for-reversing-radiation-induced-lymphopenia-in-nsclc 2024-11-10T16:06:00+00:00 weekly 0.7 https://trial.medpath.com/news/bdd192d588d01cb4/researchers-assess-the-role-of-vitamin-k2-in-managing-nocturnal-leg-cramps 2024-11-10T15:06:10+00:00 weekly 0.7 https://trial.medpath.com/news/561e2d1fdd07e45a/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-10T14:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/95a9c6bdefafa018/alzheimer-s-drug-trial-raises-concerns-for-accelerating-cognitive-decline-new-atlas 2024-11-10T14:26:11+00:00 weekly 0.7 https://trial.medpath.com/news/b01b60320a8f1a8e/harbinger-health-to-speed-up-clinical-cancer-test-validation-european-biotechnology 2024-11-10T14:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/cb7222b9397657a5/alphamab-oncology-s-promising-trial-results-bolster-prospects-markets-insider 2024-11-10T13:56:34+00:00 weekly 0.7 https://trial.medpath.com/news/eaa6b52fcc19e721/establishment-and-characterization-of-mouse-metabolic-dysfunction-associated-nature 2024-11-10T12:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/6a1b2e411fbec780/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol 2024-11-10T12:45:04+00:00 weekly 0.7 https://trial.medpath.com/news/3cdd0e10407ac366/breakthrough-discovery-links-manuka-honey-to-breast-cancer-treatment-evrim-agaci 2024-11-10T12:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/2f0ed9327801662b/elan-investor-update-did-elanco-animal-health-mislead-globenewswire 2024-11-10T12:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/21741242114ea5b4/fda-approves-self-collection-hpv-tests-as-an-alternative-to-pap-smears-columbia-missourian 2024-11-10T12:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/5d6da969edd1ad9f/the-targeted-pulse-a-review-of-last-month-s-fda-prominent-actions-and-key-data 2024-11-10T12:05:44+00:00 weekly 0.7 https://trial.medpath.com/news/16eb3f677aa73cfd/what-prevents-fda-approval-of-sublingual-immunotherapy-new-york-city-ny-patch 2024-11-10T11:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/59f0a711b3a3d49d/jnj-seeks-approval-from-usfda-ema-for-darzalex-faspro-as-subcutaneous 2024-11-10T10:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/5e0ca35bae7c7297/hyperbaric-oxygen-therapy-for-combat-associated-ptsd-psychiatrist-com 2024-11-10T10:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/f8ec910ad7725d8d/water-bead-injuries-in-children-show-alarming-rise-national-study-reports-9-requiring-escalated-care 2024-11-10T09:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/3fe519a3ae735bc4/replimune-s-rp1-shows-33-6-response-rate-in-melanoma-trial-marks-breakthrough-stock-titan 2024-11-10T09:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/5e9d200e8107cf52/earnings-call-delcath-systems-q3-2024-results-show-robust-growth-investing-com 2024-11-10T09:24:07+00:00 weekly 0.7 https://trial.medpath.com/news/f3622ab139baa102/after-germany-france-and-italy-suspend-the-astrazeneca-vaccine-of-covid-19-telegrafi 2024-11-10T07:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/08445a6a2a3dc9e7/erythropoietin-exposure-in-neonates-with-hypoxic-ischemic-encephalopathy-in-the-heal-trial 2024-11-10T07:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/de5e5cb9309e848e/early-smoking-cessation-treatment-after-cancer-diagnosis-significantly-boosts-survival-rates 2024-11-10T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/72f928a219b1dc40/corvus-pharmaceuticals-announces-new-data-highlighting-potential-of-ciforadenant-to 2024-11-10T06:56:54+00:00 weekly 0.7 https://trial.medpath.com/news/6f8927b11cab264a/fate-therapeutics-highlights-cancer-selective-her2-targeting-profile-of-ft825-ono 2024-11-10T06:47:10+00:00 weekly 0.7 https://trial.medpath.com/news/b2347360a2171804/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-10T06:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/26cc197c08b907c0/earnings-call-ocugen-outlines-progress-in-ophthalmology-trials-financials-investing-com 2024-11-10T05:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/f2a6714ce5f82916/study-reveals-strong-link-between-undiagnosed-asthma-and-insomnia-risk 2024-11-10T05:10:00+00:00 weekly 0.7 https://trial.medpath.com/news/c55deb7e4756be7d/oncoresponse-announces-phase-1-results-of-the-clinical-trial-of-or502-anti-lilrb2 2024-11-10T04:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/77f42791dddd2413/therapeutic-potential-of-neuroimmune-modulation-in-treatment-paradigm-of-relapsing 2024-11-10T04:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/0019ea54b652f30b/hong-kong-approves-celebrity-weight-loss-drug-but-experts-say-it-s-not-just-to-look-good 2024-11-10T04:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/c8dfde93968ffe0c/ama-debates-physician-compensation-for-prior-authorization-work-at-interim-meeting 2024-11-10T03:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/004e5bbeb9430bb7/bladder-cancer-treatment-paradigm-shifts-with-enfortumab-vedotin-pembrolizumab-combination-expert-highlights-at-sylvester-oncology-update 2024-11-10T03:00:48+00:00 weekly 0.7 https://trial.medpath.com/news/d91bdc3f97330e2c/day-3-recap-elevate-derm-west-2024-dermatology-times 2024-11-10T02:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/a8b062818de6b06e/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T02:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/8d90e5757477f531/lower-pharmacy-costs-give-ruxolitinib-edge-for-patients-with-mf-and-anemia 2024-11-10T01:32:04+00:00 weekly 0.7 https://trial.medpath.com/news/9c506abb978a3519/md-anderson-research-highlights-sitc-2024-special-edition 2024-11-10T01:12:21+00:00 weekly 0.7 https://trial.medpath.com/news/640d9b1a7b4d9a9d/another-signal-of-concern-with-abacavir-and-cardiovascular-risk-catie-ca 2024-11-10T00:53:50+00:00 weekly 0.7 https://trial.medpath.com/news/f3cf18dfb1cf159c/lauren-collen-md-advanced-combination-therapy-may-be-effective-option-for-pediatric 2024-11-10T00:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/41dc6dae0277dcf5/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-10T00:21:54+00:00 weekly 0.7 https://trial.medpath.com/news/9ae0f77c49a7a5f8/palvella-therapeutics-begins-phase-3-trial-for-microcystic-lymphatic-malformations-treatment 2024-11-10T00:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/8a5dedab5a8c251e/breakthrough-in-corneal-transplants-using-human-ips-cells-restores-vision-gurufocus 2024-11-10T00:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/47f711cef8ee7f6b/cab-gel-shows-promising-results-for-hispanic-patients-with-acne-dermatology-times 2024-11-10T00:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/0e186a980e291014/tarlatamab-dlle-for-previously-treated-extensive-stage-sclc 2024-11-10T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/82c1a227f7e0bd2f/icecure-medical-s-prosense-system-gains-favorable-fda-panel-recommendation-and 2024-11-09T23:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/c0a7200d81b85cd4/post-hoc-analysis-reveals-potential-serum-glycoproteomic-biomarkers-for-nivolumab-onclive 2024-11-09T23:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/6e46866380b44e8e/car-t-cell-therapy-for-kidney-cancer-builds-on-efficacy-record-medpage-today 2024-11-09T22:57:19+00:00 weekly 0.7 https://trial.medpath.com/news/383e1052c3b47aed/as-ai-transforms-drug-development-fda-is-scrambling-to-figure-out-guardrails-law-com 2024-11-09T22:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/4c5c9570f70176d0/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/0bf3815697e6a5e9/fda-proposes-ban-on-over-the-counter-decongestant-nevada-globe 2024-11-09T22:27:21+00:00 weekly 0.7 https://trial.medpath.com/news/7f0702fa2968ca82/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-09T22:27:11+00:00 weekly 0.7 https://trial.medpath.com/news/570af7fd77e8d1fc/a2-bio-highlights-progress-of-tmodtm-car-t-cell-clinical-programs-during-2024-annual 2024-11-09T22:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/b8c716ff5cc3c617/benralizumab-effectiveness-in-patients-with-severe-eosinophilic-asthm-jaa-dove-medical-press 2024-11-09T22:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/030ceeb18946b844/novel-bladder-cancer-treatment-gains-mhra-approval-in-the-uk-news-medical 2024-11-09T22:00:03+00:00 weekly 0.7 https://trial.medpath.com/news/81c11b73ed1c8c33/fate-therapeutics-highlights-cancer-selective-globenewswire 2024-11-09T21:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/1043456a96ad9603/adaptive-biotechnologies-get-expanded-medicare-coverage-of-clonoseq-for-pharmabiz-com 2024-11-09T21:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/176332e476472ba3/this-week-in-ophthalmology-week-of-november-4-2024 2024-11-09T21:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/3b4c8da08876910c/earnings-call-allogene-therapeutics-reports-on-car-t-therapy-progress-by-investing-com 2024-11-09T21:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/c18d3b6ae70fe18b/details-surrounding-phase-3-study-of-ion582-in-angelman-syndrome-announced 2024-11-09T20:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/92de81afd1c44286/delta-2-trial-shows-delgocitinib-cream-safe-with-minimal-systemic-absorption-for-chronic 2024-11-09T20:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/08786ae71dc7b80c/japanese-researchers-discover-drug-that-regenerates-teeth-in-just-6-years-union-rayo 2024-11-09T19:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/9fd2026d327859c6/askbio-receives-us-fda-rare-paediatric-disease-orphan-drug-designations-for-ab-1003-to 2024-11-09T19:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/b3aeb7bd3c1e1b9e/fixed-duration-1l-cll-treatment-reduces-long-term-costs-in-the-real-world 2024-11-09T19:18:28+00:00 weekly 0.7 https://trial.medpath.com/news/80bac08b62121766/aprea-therapeutics-reports-q3-financials-and-advances-in-clinical-trials-mychesco 2024-11-09T19:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/b7e7f220ce43f1b2/vistagen-therapeutics-promising-clinical-progress-and-strong-financial-position-justify-buy-rating 2024-11-09T19:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/cd4b8d03e07172fc/good-news-this-week-november-9-2024-dogs-ferrets-woodpeckers 2024-11-09T19:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/06cf7d045aa43f03/corvus-pharmaceuticals-announces-new-data-highlighting-globenewswire 2024-11-09T18:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/6631807dc2f967bc/team-at-mayo-clinic-in-arizona-completes-first-larynx-transplant 2024-11-09T18:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/881498d5e830aa1f/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of 2024-11-09T18:49:19+00:00 weekly 0.7 https://trial.medpath.com/news/fe55dabb565ba166/marengo-presents-promising-first-in-human-safety-tolerability-and-clinical-activity-data-for 2024-11-09T18:44:22+00:00 weekly 0.7 https://trial.medpath.com/news/e4c5553135069586/ultragenyx-pharmaceutical-inc-presents-positive-update-on-gtx-102-angelman-syndrome 2024-11-09T18:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/113e9fc30801a642/springworks-to-present-long-term-efficacy-and-safety-data-from-phase-3-defi-trial-of-ogsiveo 2024-11-09T18:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/be881bdbbfbb817a/replimune-presents-late-breaking-abstract-featuring-data-from-ignyte-clinical-trial-of-rp1 2024-11-09T18:17:42+00:00 weekly 0.7 https://trial.medpath.com/news/5cff6252f1f64f50/linaclotide-effective-for-functional-constipation-in-children-with-neurodevelopmental-disorders 2024-11-09T18:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/25ea229846e72e3e/replimune-presents-late-breaking-abstract-featuring-data-globenewswire 2024-11-09T18:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/ba53b5b9d783b09d/views-everyone-must-do-more-to-take-care-of-veterans-shaw-local 2024-11-09T18:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/3bad327e124b9ecd/pfizer-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-rimegepant-medical-dialogues 2024-11-09T17:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/c6388e80a9196c63/hold-recommendation-for-vir-biotechnology-amid-cautious-optimism-on-infectious-disease 2024-11-09T17:04:26+00:00 weekly 0.7 https://trial.medpath.com/news/39b4926bd69b5ed4/a1c-drink-inc-announces-start-of-clinical-trials-in-early-2025-targeting-a-breakthrough-in 2024-11-09T16:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/3a0da51d42014872/ga-therapies-coming-down-the-pike-modern-retina 2024-11-09T16:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/ce70af28878b07ae/oncolytic-immunotherapy-with-nivolumab-in-muscle-invasive-bladder-cancer-a-phase-1b-trial 2024-11-09T16:29:48+00:00 weekly 0.7 https://trial.medpath.com/news/c92019e3d5a67240/study-documents-detrimental-effects-of-drug-shortages-in-this-case-etoposide 2024-11-09T16:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/920efa4dd8ffeff6/earnings-call-arcturus-therapeutics-reported-a-net-loss-of-6-9-million-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/e838bea9766a747c/rhythm-pharmaceuticals-hr-chief-pamela-cramer-sells-585940-in-stock-investing-com 2024-11-09T16:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/7f0bea48e2f276f6/next-steps-for-cilta-cel-and-cartitude-4-in-multiple-myeloma-targeted-oncology 2024-11-09T16:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/802917e479da489c/ultragenyx-presents-positive-update-on-gtx-102-angelman-syndrome-program-at-fast-s 2024-11-09T15:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/e8341c36a761517e/ultragenyx-presents-positive-update-on-gtx-102-angelman-globenewswire 2024-11-09T15:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/435024ba305bf642/promising-os-at-5-years-with-chemo-free-combo-in-urothelial-cancer-medpage-today 2024-11-09T15:31:23+00:00 weekly 0.7 https://trial.medpath.com/news/a8612ae278367675/fda-approves-mi-cancer-seek-as-companion-diagnostic-for-adult-and-pediatric-patients 2024-11-09T15:07:10+00:00 weekly 0.7 https://trial.medpath.com/news/1213d46719449b5c/caligan-takes-a-stake-in-verona-pharma-sees-opportunity-to-generate-more-value-cnbc 2024-11-09T14:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/1896d798c051b514/indapta-therapeutics-presents-clinical-and-preclinical-data-of-allogenic-natural-killer-cell 2024-11-09T14:51:52+00:00 weekly 0.7 https://trial.medpath.com/news/87eccaecd001cde5/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-09T14:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/3192d2d1c17a37b9/urgent-ozempic-and-wegovy-warning-as-10-deaths-linked-to-weight-loss-jabs-the-mirror 2024-11-09T14:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/8f1ae22510bda2d0/red-flag-symptoms-of-condition-affecting-69000-women-as-hopes-grow-of-cure-surrey-live 2024-11-09T14:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/bb3c884a6ea24623/global-study-reveals-stark-disparities-in-biologic-access-for-atopic-dermatitis-treatment-across-50-countries 2024-11-09T14:00:16+00:00 weekly 0.7 https://trial.medpath.com/news/78a802a0badd5c2f/allovir-sees-a-new-direction-with-kalaris-merger-bioworld 2024-11-09T13:51:44+00:00 weekly 0.7 https://trial.medpath.com/news/d2fba6c1bd3e56c5/new-car-t-cell-therapy-approved-for-leukemia-medpage-today 2024-11-09T13:39:29+00:00 weekly 0.7 https://trial.medpath.com/news/405e2849afab8f6d/health-canada-approval-for-moderna-s-rsv-vaccine-biotechnology-the-pharmaletter 2024-11-09T13:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/ffb7584464ead3c9/the-oncfive-top-oncology-articles-for-the-week-of-11-3-onclive 2024-11-09T13:05:23+00:00 weekly 0.7 https://trial.medpath.com/news/561fc211367c508c/fda-places-hold-on-rap-219-cappricorn-1-study-to-assess-mivelsiran-in-caa-fda 2024-11-09T12:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/077fd746d9becad8/dizal-seeks-us-fda-approval-for-sunvozertinib-to-treat-relapsed-or-refractory-nsclc-with 2024-11-09T11:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/ffb7b5404fb19593/subgroup-analyses-give-weight-for-next-level-trial-of-gv1001-in-progressive-supranuclear-palsy 2024-11-09T11:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/07927435fad1def6/exclusive-clinical-trials-to-assess-health-benefits-of-ricky-kej-s-grammy-nominated 2024-11-09T11:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/cb63fedc314538e0/rising-revenue-strategic-pipeline-advances-propel-biotech-growth-trajectory 2024-11-09T10:58:14+00:00 weekly 0.7 https://trial.medpath.com/news/eaee9cd1a87bf7d4/lupin-receives-tentative-approval-from-usfda-for-raltegravir-tablets-indian-pharma-post 2024-11-09T10:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/b8048163ae610a29/weekly-review-tapinarof-cream-1-timeline-menacwy-vaccination-program-and-more 2024-11-09T10:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/f3ede8fe42bab68e/2-new-studies-highlight-issues-with-treatment-of-anaphylaxis-hcplive 2024-11-09T10:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/f922f2542ae67999/cleveland-clinic-presents-new-findings-on-triple-negative-breast-cancer-vaccine 2024-11-09T09:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/6449682607b7b08b/earnings-call-puma-biotechnology-reports-robust-q3-growth-investing-com 2024-11-09T09:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/6a042ef38be75088/entera-bio-reports-q3-2024-financial-results-and-provides-business-updates 2024-11-09T09:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/bb34c20255348ad1/aptose-reports-results-for-the-third-quarter-2024-globenewswire 2024-11-09T09:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/4de09aca43a1e1c1/u-s-drug-shortages-hit-decade-high-with-323-active-cases-ashp-reports 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eebbbe3889cb8a30/healthcare-providers-strongly-support-lowering-pneumococcal-vaccine-age-recommendation-to-50-years 2024-11-09T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/629918b6b639735a/philips-enrolls-first-patient-in-clinical-trial-for-integrated-single-device-to-treat-pad-daic 2024-11-09T08:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/04a55121bed1a5fe/at-fortune-global-forum-2024-alex-zhavoronko-eurekalert 2024-11-09T08:50:49+00:00 weekly 0.7 https://trial.medpath.com/news/e254f9479e01319e/exploring-the-current-use-and-future-of-alternatives-to-traditional-informed-consent-in-acute 2024-11-09T08:37:11+00:00 weekly 0.7 https://trial.medpath.com/news/868bc7762d5537d3/thio-plus-cemiplimab-displays-efficacy-in-checkpoint-inhibitor-resistant-nsclc 2024-11-09T08:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/8f4bc0e0fb6a2f8b/transgene-nec-to-present-new-data-confirming-clinical-proof-of-principle-for-neoantigen 2024-11-09T08:29:21+00:00 weekly 0.7 https://trial.medpath.com/news/ae3f9737735edb4a/researchers-evaluate-the-safety-and-efficacy-of-brivudine-as-oral-shingles-treatment 2024-11-09T08:25:37+00:00 weekly 0.7 https://trial.medpath.com/news/3c343fc2d93d0bde/cd47-levels-are-prognostic-of-response-to-magrolimab-plus-docetaxel-in-metastatic-nsclc 2024-11-09T08:19:30+00:00 weekly 0.7 https://trial.medpath.com/news/677d1ef9a853e7c2/combining-lutetium-psma-with-hormonal-therapy-enhances-prostate-cancer-treatment 2024-11-09T08:18:25+00:00 weekly 0.7 https://trial.medpath.com/news/e0ed40ba88e822a3/frontline-vibostolimab-pembrolizumab-plus-chemo-meets-futility-threshold-in-es-sclc 2024-11-09T08:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/4737cb67de9d3dbb/humacyte-reports-q3-2024-results-amid-fda-review-markets-insider 2024-11-09T08:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/cb60e8739145eee6/cgtlive-r-s-weekly-rewind-november-8-2024 2024-11-09T08:04:17+00:00 weekly 0.7 https://trial.medpath.com/news/076a0720a9b02d23/pd-l1-kim-1-expression-are-predictive-of-outcomes-with-adjuvant-nivolumab-alone-plus 2024-11-09T07:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/8dacdae00f2c9b77/autolus-wins-fda-approval-of-aucatzyl-for-acute-lymphoblastic-leukemia-seeking-alpha 2024-11-09T07:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/6ba2adb86559826d/j-j-s-balversa-gains-mhra-marketing-authorization-as-monotherapy-for-bladder-cancer 2024-11-09T06:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/f6c6e060a7d8be63/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-here-s-why 2024-11-09T06:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/81e3d577b65435f1/fda-renews-reduced-risk-authorization-for-eight-swedish-match-products 2024-11-09T06:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/ddac2bc2f70c5456/efficacy-and-safety-evaluation-of-a-novel-hemostatic-gelatin-matrix-for-intraoperative-hemostasis 2024-11-09T06:01:10+00:00 weekly 0.7 https://trial.medpath.com/news/1d930a5eb89b7f36/trontinemab-data-strengthen-hope-for-brain-shuttles-alzforum 2024-11-09T06:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/adc52945bfc48b63/fda-accepts-bla-for-shanghai-henlius-biotech-s-and-organon-s-hlx14-a-denosumab-biosimilar 2024-11-09T05:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/a95e592e69a742e3/boston-scientific-resumes-study-of-pulse-field-ablation-as-first-line-afib-therapy 2024-11-09T05:35:15+00:00 weekly 0.7 https://trial.medpath.com/news/684db857a226cd68/kura-oncology-positioned-for-growth-with-promising-trial-developments-and-strong-financials 2024-11-09T05:31:43+00:00 weekly 0.7 https://trial.medpath.com/news/a725dc145f53197d/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-webwire 2024-11-09T05:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/a6d720f11333a9e3/treatment-offers-promise-for-terrible-terrible-brain-cancer-in-young-people 2024-11-09T05:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/2a99337a7be126bf/trump-s-2024-election-victory-signals-major-shifts-in-us-healthcare-policy 2024-11-09T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1d61237a3cc15a86/dr-dimopoulos-on-efficacy-findings-from-the-dreamm-8-trial-in-multiple-myeloma 2024-11-09T04:54:47+00:00 weekly 0.7 https://trial.medpath.com/news/3eae29b06c47e2b0/fda-s-october-approvals-include-the-first-cldn18-2-mab-biocentury 2024-11-09T04:53:38+00:00 weekly 0.7 https://trial.medpath.com/news/6dbe8c0db0c626a7/year-in-review-multiple-sclerosis-medpage-today 2024-11-09T04:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/5b4987e8c1e824e8/lurie-children-s-developing-optical-genome-mapping-test-for-brain-tumors 2024-11-09T04:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/5aecb92d83d582f6/donanemab-small-tweak-in-titration-big-gain-in-safety-alzforum 2024-11-09T03:21:38+00:00 weekly 0.7 https://trial.medpath.com/news/adc2c861aab75942/huyabio-presents-positive-phase-2-data-on-hbi-8000-and-nivolumab-combination-for 2024-11-09T03:15:10+00:00 weekly 0.7 https://trial.medpath.com/news/f78f8688561990ae/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/981c427e7de7b41f/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-biospace 2024-11-09T03:15:09+00:00 weekly 0.7 https://trial.medpath.com/news/062ef2ad8703836e/axsome-therapeutics-presents-data-from-its-leading-neuroscience-pipeline-at-nei-congress-2024 2024-11-09T03:15:07+00:00 weekly 0.7 https://trial.medpath.com/news/6f36d147b8df6279/sec-recommends-approval-for-msn-laboratories-sleep-disorder-drug-pharmabiz-com 2024-11-09T02:29:50+00:00 weekly 0.7 https://trial.medpath.com/news/d24e89804a7170cd/dostarlimab-plus-chemo-yield-strong-survival-results-in-metastatic-nsclc 2024-11-09T02:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/317b85f087d69320/clinical-trial-offers-new-hope-for-weight-loss-seekers-local-12 2024-11-09T02:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/7aa37fca103f7fbc/bioatla-inc-bcab-q3-2024-earnings-call-highlights-strategic-a-gurufocus 2024-11-09T01:58:49+00:00 weekly 0.7 https://trial.medpath.com/news/80239cd065927250/tempus-ai-unveils-breakthrough-cancer-treatment-algorithm-cost-saving-study-at-sitc-2024 2024-11-09T00:47:44+00:00 weekly 0.7 https://trial.medpath.com/news/b50a53f580bab72e/ntla-2002-gene-editing-reduces-angioedema-attacks-in-hereditary-angioedema 2024-11-09T00:09:23+00:00 weekly 0.7 https://trial.medpath.com/news/f25970a2565208d7/maia-biotechnology-inc-filed-sec-form-8-k-regulation-fd-disclosure-financial 2024-11-09T00:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/a382efa67194d6e6/clinical-trials-on-alzheimer-s-disease-ctad-2023-16th-alzforum 2024-11-09T00:00:42+00:00 weekly 0.7 https://trial.medpath.com/news/9fa6b2b72d500a07/merck-s-keytruda-r-pembrolizumab-significantly 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/930b2f4f3bc20777/merck-statement-on-fda-advisory-committee-meeting-for-zinplava 2024-11-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d9a088f3f788d79f/tezspire-phase-iii-nasal-polyp-data-may-lead-to-second-indication-citeline 2024-11-08T23:18:30+00:00 weekly 0.7 https://trial.medpath.com/news/fbf5327fd5eb7bf6/autolus-therapeutics-gets-fda-approval-for-cancer-treatment-morningstar 2024-11-08T23:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/4bb9e15c633f0eb4/evolving-role-of-mrd-status-in-multiple-myeloma-the-asco-post 2024-11-08T23:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/5881830d16795828/fda-approves-obecabtagene-autoleucel-for-adult-leukemia-treatment-healio 2024-11-08T22:59:10+00:00 weekly 0.7 https://trial.medpath.com/news/47c58b4ac6d55f4e/zealand-s-amylin-obesity-drug-could-rival-novo-s-but-it-needs-a-partner-citeline 2024-11-08T22:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/cb66d946e0e9539e/3-latest-medical-breakthroughs-to-know-about-in-2024 2024-11-08T22:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/6d760402cf70c64a/astrazeneca-plc-tezspire-meets-primary-endpoints-in-waypoint-trial 2024-11-08T22:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/741d5298ed7a887b/fda-approves-obe-cel-for-adults-with-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T22:19:14+00:00 weekly 0.7 https://trial.medpath.com/news/d1667492e4f89e34/unexpected-results-in-solid-tumors-what-we-learned-from-negative-findings 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/044a561a87acebf1/eyeing-the-future-of-oncology-highlights-from-the-presidential-symposium-at-esmo-congress-2024 2024-11-08T22:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/5822193a9ab6bd4c/fda-approves-aucatzyl-for-adults-with-aggressive-leukemia 2024-11-08T22:15:48+00:00 weekly 0.7 https://trial.medpath.com/news/252c382869c40a5c/fda-approves-obe-cel-for-r-r-b-cell-acute-lymphoblastic-leukemia 2024-11-08T22:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/f458f2b3b9a47915/positive-trials-continue-to-shape-the-sclc-treatment-landscape-targeted-oncology 2024-11-08T22:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/2aa8d185fe137490/fda-approves-obecabtagene-autoleucel-for-relapsed-refractory-b-cell-precursor-all 2024-11-08T22:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/0415d9fd515eaa84/fda-renews-authorization-for-eight-general-snus-products-nacs 2024-11-08T21:50:08+00:00 weekly 0.7 https://trial.medpath.com/news/1b18ac7a832ea173/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/5ce7599bdf67c948/fda-approves-car-t-cell-therapy-for-relapsed-or-refractory-b-cell-all-cure-today 2024-11-08T21:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/2959c8b7f014e044/fda-approves-obecabtagene-autoleucel-in-b-cell-all-cancer-network 2024-11-08T21:27:57+00:00 weekly 0.7 https://trial.medpath.com/news/5ab28a407ed6168f/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-obecabtagene-autoleucel 2024-11-08T21:26:53+00:00 weekly 0.7 https://trial.medpath.com/news/6f686636ef9f37b9/autolus-therapeutics-announces-fda-approval-of-aucatzyl-r-globenewswire 2024-11-08T21:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/20eaad34250ab6ce/fda-approves-obecabtagene-autoleucel-for-r-r-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-08T21:18:32+00:00 weekly 0.7 https://trial.medpath.com/news/5f2515a770eda598/ima203-shows-frequent-enduring-responses-and-tolerability-in-melanoma 2024-11-08T21:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/eb6f09190630b563/kiromic-biopharma-inc-sec-10-q-report-tradingview 2024-11-08T21:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/3e50804948867773/fda-approves-aucatzyl-obecabtagene-autoleucel-for-adults-with-relapsed-refractory-b-cell-acute-lymphoblastic-leukemia 2024-11-08T21:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/2e5f9d6584cc530a/astrazeneca-successful-phase-iii-trial-for-tezspire-marketscreener 2024-11-08T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/8f0c140462d47b4a/fda-greenlights-obe-cel-in-relapsed-refractory-b-all-targeted-oncology 2024-11-08T21:05:22+00:00 weekly 0.7 https://trial.medpath.com/news/066f71ce69927146/neoadjuvant-therapy-yields-notable-outcomes-in-triple-negative-breast-cancer 2024-11-08T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/9d4e41c04a27ebfb/cue-biopharma-presents-positive-updated-data-from-its-phase-1-trials-of-cue-101-biospace 2024-11-08T20:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/7f77e172982044a0/frontline-dostarlimab-chemo-maintains-numerical-os-benefit-in-advanced-nsclc 2024-11-08T20:49:34+00:00 weekly 0.7 https://trial.medpath.com/news/4d96ea732e516713/johnson-johnson-submits-applications-for-new-indications-for-darzalex-markets-insider 2024-11-08T20:15:39+00:00 weekly 0.7 https://trial.medpath.com/news/8fff1a37c2722d13/former-fitness-instructor-beyond-excited-to-receive-lupus-therapy-in-uk-first 2024-11-08T20:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/c41a39923b0a13f3/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T19:55:42+00:00 weekly 0.7 https://trial.medpath.com/news/69448170ec843702/bristol-myers-squibb-leads-biopharma-recovery-with-almost-25-growth-in-market-cap 2024-11-08T19:38:56+00:00 weekly 0.7 https://trial.medpath.com/news/b22bc476e02dc8af/remembering-bruce-albala-70-leader-in-bace-inhibitor-development-alzforum 2024-11-08T19:31:41+00:00 weekly 0.7 https://trial.medpath.com/news/4233d32755f1f04b/fda-takes-step-toward-removal-of-ineffective-decongestants-from-the-market 2024-11-08T18:56:12+00:00 weekly 0.7 https://trial.medpath.com/news/a48787be4ffa9365/cue-biopharma-cancer-drug-trial-soars-91-survival-rate-shatters-expectations 2024-11-08T18:54:57+00:00 weekly 0.7 https://trial.medpath.com/news/5188acf6b9be6189/senseonics-has-mixed-q3-results-positive-eversense-365-outlook-drug-delivery-business 2024-11-08T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/7144d42a26c6e527/cue-biopharma-presents-positive-updated-data-from-its-phase-globenewswire 2024-11-08T18:46:28+00:00 weekly 0.7 https://trial.medpath.com/news/23b5dd2b5963d432/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T18:28:29+00:00 weekly 0.7 https://trial.medpath.com/news/a72bacd989114b85/cmn-weekly-8-november-2024-your-weekly-crispr-medicine-news 2024-11-08T18:26:58+00:00 weekly 0.7 https://trial.medpath.com/news/5ca5a224bfd13b27/lupin-receives-us-fda-tentative-approval-for-raltegravir-tablets-usp-pharmabiz-com 2024-11-08T18:25:49+00:00 weekly 0.7 https://trial.medpath.com/news/e402e816a7bd21ad/maia-biotechnology-reveals-promising-phase-2-trial-results-tipranks-com 2024-11-08T18:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/21b1bba9783c1e61/sunvozertinib-nda-submitted-to-fda-for-nsclc 2024-11-08T18:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/ebd1ee21901bf119/md-anderson-launches-institute-for-cell-therapy-discovery-innovation-to-deliver 2024-11-08T18:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/10392422f41bd31a/kiora-pharmaceuticals-reports-third-quarter-results-retinal-disease-pipeline-advancing 2024-11-08T18:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/ddd95dc3b029c095/ondine-biomedical-life-sciences-company-raises-c-16-million-pulse-2-0 2024-11-08T18:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/ef3a5a8123c07ff3/alzheimer-s-disease-what-treatments-could-be-rolled-out-in-the-next-few-years-the-bmj 2024-11-08T17:48:15+00:00 weekly 0.7 https://trial.medpath.com/news/e88b793f9a81d30d/fda-approval-sought-for-sunvozertinib-in-pretreated-egfr-exon-20-advanced-nsclc 2024-11-08T17:38:34+00:00 weekly 0.7 https://trial.medpath.com/news/8747810f2ab1bcfd/modified-kisunla-dosing-lowers-risk-of-aria-e-in-alzheimer-s-study 2024-11-08T17:10:31+00:00 weekly 0.7 https://trial.medpath.com/news/5309362c45cb08a9/kineta-updates-kva12123-clinical-results-from-ongoing-phase-1-2-vista101-study-at 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/b95dae1de5dc862a/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T17:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/a9e3221d2d86d513/monopar-therapeutics-reports-third-quarter-2024-financial-results-and-recent-developments 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/b0ad7525c7530720/systimmune-inc-announces-fda-clearance-of-ind-application-for-bl-m17d1-in-advanced 2024-11-08T17:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/28b4abdb92462496/md-anderson-launches-institute-for-cell-therapy-di-newswise 2024-11-08T17:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/09416c8d27eb3d3e/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-myeloma 2024-11-08T17:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/0406d4c0fecda297/mb-108-gains-fda-orphan-drug-status-for-malignant-glioma-treatment 2024-11-08T17:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/6a60f6ed90da0d03/hurricane-helene-delays-spectral-medical-s-confirmatory-trial-enrolment 2024-11-08T16:59:53+00:00 weekly 0.7 https://trial.medpath.com/news/4ee1bd5635310ce9/fda-plans-to-ban-ineffective-cold-medicine-ingredient-how-it-will-affect-you-health 2024-11-08T16:52:17+00:00 weekly 0.7 https://trial.medpath.com/news/beee82d48ea51bfc/relmada-therapeutics-hopes-to-hit-big-milestones-by-year-end 2024-11-08T16:50:20+00:00 weekly 0.7 https://trial.medpath.com/news/2ae7b24e74e44bf9/fda-grants-orphan-drug-designation-to-ifetroban-for-treatment-of-duchenne-muscular 2024-11-08T16:46:23+00:00 weekly 0.7 https://trial.medpath.com/news/dba0f39de0977eae/fda-ema-receive-applications-for-subcutaneous-daratumumab-in-high-risk-smoldering-myeloma 2024-11-08T16:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/c28ffab9b0579e09/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/d8d004f69eb01b45/tezspire-succeeds-in-chronic-rhinosinusitis-gilead-writes-down-trodelvy-value 2024-11-08T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/6b8df60dff0b9a02/oncoresponse-reports-data-of-phase-i-solid-tumour-treatment-trial-clinical-trials-arena 2024-11-08T16:24:31+00:00 weekly 0.7 https://trial.medpath.com/news/2082546735081b9e/alignment-extending-our-clinical-trials-to-more-patients-yale-school-of-medicine 2024-11-08T16:22:03+00:00 weekly 0.7 https://trial.medpath.com/news/632407f1f225eb9b/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T16:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/1916c86bf2d2dd08/les-turner-symposium-on-als-unites-community-around-research-and-patient-care 2024-11-08T16:05:52+00:00 weekly 0.7 https://trial.medpath.com/news/677f9f5c88982bb6/fda-approves-johnson-johnson-s-varipulse-for-drug-resistant-paroxysmal-atrial-fibrillation 2024-11-08T15:47:56+00:00 weekly 0.7 https://trial.medpath.com/news/c249a94b26f2d13b/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-08T15:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/f1f03b5f666668c9/cervomed-awarded-the-prix-galien-usa-2024-prize-for-best-startup-the-globe-and-mail 2024-11-08T15:40:22+00:00 weekly 0.7 https://trial.medpath.com/news/e2f47f1e33829865/nivolumab-plus-ipilimumab-in-aggressive-thyroid-carcinoma-the-asco-post 2024-11-08T15:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/d87b099a14bfd760/sunvozertinib-new-drug-application-in-egfr-mutant-nsclc-submitted-to-fda 2024-11-08T15:35:34+00:00 weekly 0.7 https://trial.medpath.com/news/5dd94f77e170312e/compass-therapeutics-reveals-breakthrough-biomarker-data-for-cancer-drug-ctx-471 2024-11-08T15:15:02+00:00 weekly 0.7 https://trial.medpath.com/news/387d4e9d4c9616fd/fda-roundup-rosacea-treatment-proposal-to-remove-oral-phenylephrine-from-otc-products 2024-11-08T15:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/7dd82712ebb3f454/pediatric-gastroparesis-hospitalizations-surge-post-covid-19-chop-study-reveals 2024-11-08T15:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/4d55d992609010cd/johnson-johnson-seeks-approval-of-darzalex-faspro-in-us-darzalex-in-eu-for-myeloma 2024-11-08T15:05:58+00:00 weekly 0.7 https://trial.medpath.com/news/8b26741c07a34883/year-in-review-rsv-medpage-today 2024-11-08T15:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/64aedd9dfd2104eb/dogwood-therapeutics-inc-sec-10-q-report-tradingview 2024-11-08T15:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/0c623cfc329d4a68/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T15:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/33445f2265061b47/skyrizi-overtakes-humira-in-u-s-sales-numbers-managed-healthcare-executive 2024-11-08T15:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/c6cea1cab2048424/expert-comments-on-the-risks-and-benefits-of-tirzepatide-following-the-death-of-susan-mcgowan 2024-11-08T14:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/8a27babcf1d67aa9/uclh-announces-start-of-car-t-cell-therapy-clinical-trial-for-lupus-patients 2024-11-08T14:38:41+00:00 weekly 0.7 https://trial.medpath.com/news/6a0d5f5449c8488b/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets 2024-11-08T14:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/35bd8c5c3f2068ec/fda-to-pull-common-but-ineffective-cold-medicine-from-market-cbs-news 2024-11-08T14:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/9ef35003af539cd7/iag-beats-on-q3-revenue-astrazeneca-discloses-positive-phase-3-clinical-trial 2024-11-08T14:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/648b699c6fe8a723/extrachromosomal-dna-spread-oncogenic-traits-add-synthetic-lethal-targets 2024-11-08T14:27:20+00:00 weekly 0.7 https://trial.medpath.com/news/5d1521d043d72e72/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine 2024-11-08T14:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/29a2a239fed09af8/cidara-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-08T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/ce54122ebfec6c1b/cofactor-s-cancer-biomarker-test-outshines-standard-ici-predictive-tests 2024-11-08T14:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/da22e9da3a976bb0/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic-rhinosinusitis-with-nasal-polyps 2024-11-08T14:17:50+00:00 weekly 0.7 https://trial.medpath.com/news/f5a1a2c200aad2dc/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:15:53+00:00 weekly 0.7 https://trial.medpath.com/news/7ed4692ab294e323/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/be999935ef7f8485/biostock-full-phase-ii-results-of-upar-pet-in-glioblastoma-published-cision-news 2024-11-08T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/6ebd70f8f0fe4fc5/sana-biotechnology-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-08T14:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/29c2041e5789771b/luspatercept-improved-diagnostics-deliver-in-mds-targeted-oncology 2024-11-08T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/38d44680d95e61ee/fda-authorizes-marketing-for-first-combination-flu-and-covid-19-at-home-test-outside-of 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/c63a82ecc82478bb/fda-approves-the-first-flu-vaccine-for-at-home-use-providing-a-needle-free-option-akin-gump 2024-11-08T13:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/09b4d5f8096ccc62/cancer-therapy-with-potential-to-transform-lupus-treatment-delivered-in-manchester-in-uk-first 2024-11-08T13:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/00a1b23c8885a524/astrazeneca-says-phase-iii-waypoint-study-of-tezspire-met-primary-goals-rttnews 2024-11-08T13:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/72106f47ece8903a/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-08T13:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/7b2ed64cf84c297f/xilio-therapeutics-announces-initial-clinical-trial-data-from-phase-1c-dose-escalation-biospace 2024-11-08T13:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/5a08a52bcd019cc4/immunovant-provides-development-updates-and-reports-financial-results-for-the-quarter 2024-11-08T13:40:54+00:00 weekly 0.7 https://trial.medpath.com/news/36a5ce86e4536f42/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T13:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/919baa1ee9854c99/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-08T13:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/242e8d18e0986b57/j-j-medtech-receives-us-fda-approval-for-varipulse-pfa-platform-in-af-treatment 2024-11-08T13:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/cf04b9068653e0bf/fda-approves-j-j-s-device-for-heart-condition-healthleaders-media 2024-11-08T13:28:38+00:00 weekly 0.7 https://trial.medpath.com/news/0bb368c337523a14/mariposa-2-second-interim-survival-data-targeted-oncology 2024-11-08T13:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/a07899007a390fcc/ncats-award-to-support-multi-site-study-evaluating-remote-trials-university-at-buffalo 2024-11-08T13:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/9283e9ba630c09c6/minn-ems-looks-to-enroll-trauma-patients-in-blood-loss-drug-trials-ems1 2024-11-08T13:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/f5dbf4808fdbfe0b/johnson-johnson-submits-applications-in-the-u-s-and-eu-seek-approval-of-darzalex 2024-11-08T13:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/bc40ecae15f36e82/cleveland-clinic-announces-updated-findings-in-preventive-breast-cancer-vaccine-study 2024-11-08T13:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/3bfdb54faece2e45/johnson-johnson-seeks-fda-ema-nod-for-myeloma-treatment-investing-com 2024-11-08T12:51:53+00:00 weekly 0.7 https://trial.medpath.com/news/23a64a22e40a524f/astrazeneca-and-amgen-s-tezspire-succeeds-in-phase-iii-nasal-polyps-trial 2024-11-08T12:46:19+00:00 weekly 0.7 https://trial.medpath.com/news/001903c633e73f2a/inflarx-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/05d369be1dc60932/south-africa-becomes-a-key-player-in-astrazeneca-s-global-clinical-trial-success 2024-11-08T12:41:24+00:00 weekly 0.7 https://trial.medpath.com/news/713526ce86ee3936/meeting-highlights-from-the-committee-for-veterinary-medicinal-products-cvmp-5-7 2024-11-08T12:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/ede8218a6a4c9be3/icecure-s-prosense-cancer-treatment-wins-crucial-fda-panel-vote-shares-surge 2024-11-08T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/b073bfc99c876be4/study-shows-sglt2i-drugs-are-safe-for-patients-with-cirrhosis-consult-qd 2024-11-08T12:35:22+00:00 weekly 0.7 https://trial.medpath.com/news/94ded1254b1e895b/who-announces-priority-endemic-pathogens-for-urgent-vaccine-development-pmlive 2024-11-08T12:28:23+00:00 weekly 0.7 https://trial.medpath.com/news/3a0edeb1febd90cd/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-markets-insider 2024-11-08T12:24:49+00:00 weekly 0.7 https://trial.medpath.com/news/c3c85268464a9b3b/uk-study-shows-rsv-vaccine-could-reduce-antibiotic-use-and-antimicrobial-resistance 2024-11-08T12:23:56+00:00 weekly 0.7 https://trial.medpath.com/news/a2213a127096f29a/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/f01e24fc0c53d630/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T12:21:48+00:00 weekly 0.7 https://trial.medpath.com/news/de0b42be70e90d07/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:13:54+00:00 weekly 0.7 https://trial.medpath.com/news/21ae01fdcd2c6d92/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/12633987a41e4911/the-uk-developed-handheld-scanner-that-could-revolutionise-medical-imaging-the-engineer 2024-11-08T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/05635585eb012ab3/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-08T12:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/1e90d0863c30b432/johnson-johnson-submits-applications-in-the-u-s-and-eu-globenewswire 2024-11-08T12:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/a7b743cdf4211abb/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus 2024-11-08T12:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/a23ca06be6bee504/johnson-johnson-submits-applications-in-the-u-s-and-eu-seeking-approval-of-pr-newswire 2024-11-08T12:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/b181a4f4c764ef25/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T12:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/7a7d06403d36bd60/averitas-completes-recruitment-for-trial-of-qutenza-to-treat-post-surgical-pain 2024-11-08T11:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/0d629889d78fa9f0/cancer-care-evolution-industry-leaders-address-quadruple-aim-challenges-and-opportunities 2024-11-08T11:53:41+00:00 weekly 0.7 https://trial.medpath.com/news/fde185a23cefb33c/ocugen-provides-business-update-with-third-quarter-2024-financial-results-globenewswire 2024-11-08T11:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/c4b4a3638e17cdae/dizal-pharmaceutical-co-ltd-submits-new-drug-application-to-the-u-s-fda-for-marketscreener 2024-11-08T11:43:36+00:00 weekly 0.7 https://trial.medpath.com/news/b16637ba5aec230d/babyfox-study-to-assess-impact-of-ultrafast-whole-genome-sequencing-on-nicu-care-for 2024-11-08T11:42:13+00:00 weekly 0.7 https://trial.medpath.com/news/7f03818c88fe8036/dicot-pharma-announces-initiation-of-phase-2a-clinical-study-cision-news 2024-11-08T11:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/59723c197f6137db/johnson-johnson-medtech-s-varipulse-platform-receives-fda-approval-for-afib 2024-11-08T11:34:56+00:00 weekly 0.7 https://trial.medpath.com/news/d001f409bf2b93a6/novel-dll3-topabody-shows-promising-preclinical-results-for-small-cell-lung-cancer-treatment 2024-11-08T11:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/56f7154c64bfe38d/phase-ii-trial-of-multi-tyrosine-kinase-inhibitor-esk981-in-combination-with-pd-1-urotoday 2024-11-08T11:30:23+00:00 weekly 0.7 https://trial.medpath.com/news/f494350564cff1e0/a-36-gene-predictive-score-of-anti-cancer-dru-eurekalert 2024-11-08T11:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/5fcc71c9a8ca5c81/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T11:21:31+00:00 weekly 0.7 https://trial.medpath.com/news/b832216962be9938/recruitment-underway-for-a-clinical-trial-testing-new-vaccine-against-respiratory-viruses 2024-11-08T11:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/31a20d9b883d6685/fda-suggests-removing-nonprescription-decongestant-from-market 2024-11-08T11:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/28ef11653e2b7a7b/altimmune-announces-successful-completion-of-end-of-phase-2-meeting-with-fda-for 2024-11-08T11:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/ddb1df80dbd68970/radella-reports-positive-outcomes-from-trial-of-md-18-for-obesity-and-diabetes 2024-11-08T11:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/036b97556046dc8d/smallpox-drug-in-clinical-trials-for-treating-mpox-in-africa 2024-11-08T10:41:32+00:00 weekly 0.7 https://trial.medpath.com/news/7a1814a4a68be3a0/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed 2024-11-08T10:16:34+00:00 weekly 0.7 https://trial.medpath.com/news/abbd6063ad2fa972/ncc-premia-paradigm-unveil-nationwide-clinical-trial-network-in-japan-healthcare-asia 2024-11-08T10:10:52+00:00 weekly 0.7 https://trial.medpath.com/news/1f4ba9926732b177/determining-doses-for-backfill-cohorts-based-on-patient-reported-outcome 2024-11-08T09:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/88550ec92b55fe69/da-expects-approval-of-asf-vaccine-for-commercial-use-by-yearend-abs-cbn-news 2024-11-08T09:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/874c56fa29ae2659/metabolic-markers-linked-to-cognitive-decline-in-multiple-sclerosis-patients-study-finds 2024-11-08T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bc2b06b068c54f70/astrazeneca-rises-after-asthma-medicine-meets-primary-goals-in-phase-3-trial-tradingview 2024-11-08T08:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/e33e648244ac6b16/astrazeneca-hails-positive-phase-iii-data-for-repurposed-asthma-treatment-lse-azn 2024-11-08T07:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/9fa10984e15884eb/industry-leaders-unite-to-tackle-patient-recruitment-challenges-in-rare-disease-clinical-trials 2024-11-08T07:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/2a4a8f7ced094434/wvu-cancer-institute-first-to-use-fda-approved-device-for-esophageal-cancer-prevention 2024-11-08T07:49:23+00:00 weekly 0.7 https://trial.medpath.com/news/1a7773668295df85/astrazeneca-s-tezspire-shows-promise-in-phase-iii-trial-tipranks-com 2024-11-08T07:43:58+00:00 weekly 0.7 https://trial.medpath.com/news/7b3995e1dc0facfa/combining-the-vigex-gene-expression-signature-eurekalert 2024-11-08T07:26:33+00:00 weekly 0.7 https://trial.medpath.com/news/b0dbfe4eafe91e5f/dr-ashraf-on-the-utility-of-t-dxd-in-her2-mutated-nsclc-onclive 2024-11-08T07:23:43+00:00 weekly 0.7 https://trial.medpath.com/news/e8a253d262e80904/tezspire-met-both-co-primary-endpoints-in-phase-3-trial-for-chronic 2024-11-08T07:13:30+00:00 weekly 0.7 https://trial.medpath.com/news/6137bc95a0cdaffb/fox-chase-cancer-center-appoints-renowned-immunotherapy-expert-dr-lorenzo-galluzzi-as-associate-professor 2024-11-08T07:08:52+00:00 weekly 0.7 https://trial.medpath.com/news/a941411065987182/tezspire-met-both-co-primary-endpoints-in-the-phase-iii-waypoint-trial-in-patients-with 2024-11-08T07:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/09c25bf81e967e16/ciie-helping-gilead-sciences-boost-development-in-china-chinadaily-com-cn 2024-11-08T06:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/ea4aed9f5d9596f8/skye-bioscience-reports-progress-in-obesity-drug-trials-tipranks-com 2024-11-08T06:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/0fd3f89a801806f2/egetis-therapeutics-interim-report-q3-2024-mfn-placera 2024-11-08T06:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/130056ee4510c2e5/clinical-trials-how-patients-and-scientists-team-up-to-fight-cancer-north-bay-news 2024-11-08T06:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/821a82fbb5996aef/positive-outlook-and-buy-rating-for-protagonist-therapeutics-based-on-promising-phase-iii 2024-11-08T05:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/6bb0101a31ae7cff/after-decades-fda-finally-moves-to-pull-ineffective-decongestant-off-shelves-ars-technica 2024-11-08T05:44:51+00:00 weekly 0.7 https://trial.medpath.com/news/b2c9c9b6066ce171/us-fda-approves-johnson-johnson-s-device-for-heart-condition-et-healthworld 2024-11-08T05:43:45+00:00 weekly 0.7 https://trial.medpath.com/news/9b6b05a4496368c2/fda-adds-new-warning-to-weight-loss-drugs-including-wegovy-dallas-morning-news 2024-11-08T05:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/e7b2410dca1d64f9/fda-approval-of-j-j-s-varipulse-ramps-up-pfa-competition-bioworld 2024-11-08T04:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/8ea54df43c99dbba/nebraska-medicine-finds-success-with-first-of-its-kind-cancer-treatment-wowt 2024-11-08T04:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/a5fe828f80bfef28/puma-biotechnology-reports-third-quarter-2024-financial-results-biospace 2024-11-08T04:43:26+00:00 weekly 0.7 https://trial.medpath.com/news/a7e44cfe2a15166b/lupus-breakthrough-as-groundbreaking-new-nhs-therapy-could-offer-cure-for-it-and-ms 2024-11-08T04:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/b91c26b2046876ad/palleon-pharmaceuticals-presents-results-from-the-phase-1-2-glimmer-01-trial-of-e-602-in-combination-with-cemiplimab-in-patients-with-solid-tumors-at-the-society-for-immunotherapy-of-cancer-sitc-annual-meeting 2024-11-08T03:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/80fb43c4c16d219c/dizal-submits-new-drug-application-to-the-u-s-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations 2024-11-08T03:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/761d43f31f61d65d/dr-pedro-martinez-clark-founder-of-amavita-heart-and-vasculartm-partners-with-limflow 2024-11-08T03:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/c024050ce3c58bd7/atossa-s-endoxifen-shows-promise-in-reducing-mammographic-breast-density-in-phase-ii-trial 2024-11-08T02:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/4dd2fc69757b7108/sec-recommends-marketing-approval-for-dr-reddy-s-spms-drug-siponimod-tablets 2024-11-08T02:29:20+00:00 weekly 0.7 https://trial.medpath.com/news/7bd7fc57634db266/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher-motley-fool 2024-11-08T02:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/e6f12a9072760d03/xilio-therapeutics-announces-initial-clinical-trial-data-globenewswire 2024-11-08T02:16:07+00:00 weekly 0.7 https://trial.medpath.com/news/d79e963148838e43/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-08T02:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/ea1d0d9b4a1b823f/avidity-biosciences-initiates-biomarker-cohort-in-phase-1-2-fortitude-trial-seeks 2024-11-08T02:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/b023abbd90dd34be/astrazeneca-s-china-president-detained-amid-widening-investigation-into-drug-related-violations 2024-11-08T01:45:11+00:00 weekly 0.7 https://trial.medpath.com/news/62e118bfa974ed30/rezolute-reports-first-quarter-fiscal-2025-financial-results-and-provides-business-update 2024-11-08T01:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/681179aeee35f422/data-from-transgene-and-nec-confirm-proof-of-principle-for-cancer-vaccine-tg4050 2024-11-08T01:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/23bc9eed8d98befd/imugene-opens-first-australian-site-for-azer-cel-clinical-trial-targeting-lymphoma 2024-11-08T00:51:58+00:00 weekly 0.7 https://trial.medpath.com/news/5776aa699f976100/dr-parikh-on-available-treatment-options-for-her2-crc-onclive 2024-11-08T00:40:23+00:00 weekly 0.7 https://trial.medpath.com/news/abc13ae25391ef85/dr-powell-on-the-implications-of-the-fda-approval-of-dostarlimab-for-endometrial-cancer 2024-11-08T00:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/eefc083b7c74634b/three-patient-receive-groundbreaking-lupus-treatment-in-the-uk-the-independent 2024-11-08T00:18:55+00:00 weekly 0.7 https://trial.medpath.com/news/30414b79e0e0a934/first-line-benmelstobart-plus-anlotinib-and-chemotherapy-in-advanced-or-metastatic-nature 2024-11-08T00:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/83821c8ad3a82d17/three-patients-in-the-uk-receive-groundbreaking-treatment-for-lupus-wandsworth-times 2024-11-08T00:13:52+00:00 weekly 0.7 https://trial.medpath.com/news/5499944dec4bec81/news-events-pilatus-biosciences 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e366f701a41593cf/huons-acquires-31-53-stake-in-pangen-biotech-for-10-4-million-to-advance-biopharmaceutical-cdmo-business 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f3797bf80672f24b/emerging-insights-into-til-therapy-a-new-horizon-in-cancer-treatment 2024-11-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6746592686cf3cec/uk-s-nhs-data-access-barriers-impede-critical-medical-research-sudlow-review-warns 2024-11-07T23:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/1ac6d1dd56112583/emory-study-estimates-millions-with-depression-could-benefit-from-psychedelic-mushrooms 2024-11-07T23:37:42+00:00 weekly 0.7 https://trial.medpath.com/news/a3d041faefcb80c0/efficacy-of-hiv-combination-antiretroviral-medication-in-black-individuals-contagion-live 2024-11-07T23:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/06baed8d6e613fd4/vanda-seeks-new-markets-for-hetlioz-amid-generic-competition-sleep-review 2024-11-07T23:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/f46cef2b8364de33/89bio-inc-sec-10-q-report-tradingview 2024-11-07T23:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/16d43c2416c1284b/esperion-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T23:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/06886d7e669d425d/repare-therapeutics-provides-business-and-clinical-update-and-reports-third-quarter 2024-11-07T23:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/495803c17e24a8d6/achieve-life-sciences-reports-financial-results-for-third-quarter-2024-and-provides 2024-11-07T22:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/a09442c2d4df8de5/alx-oncology-holdings-inc-sec-10-q-report-tradingview 2024-11-07T22:24:16+00:00 weekly 0.7 https://trial.medpath.com/news/9d578ccf13c8fb3d/johnson-johnson-medtech-gains-fda-approval-for-varipulse-pfa-system 2024-11-07T22:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/d40a65b4761853b7/longboard-pharmaceuticals-reports-third-quarter-2024-financial-results-and-provides 2024-11-07T22:13:21+00:00 weekly 0.7 https://trial.medpath.com/news/fabf7ff6ae9277af/ecog-acrin-and-precog-announce-multiple-presentations-at-ash-2024-eurekalert 2024-11-07T22:00:38+00:00 weekly 0.7 https://trial.medpath.com/news/2a181e94f4474f01/sarepta-discontinues-work-on-next-gen-exon-skipping-drug-for-duchenne-endpoints-news 2024-11-07T21:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/fd49b9642c2503c2/field-medical-s-fieldforce-pfa-system-receives-fda-breakthrough-designation-for-ventricular-tachycardia-treatment 2024-11-07T21:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/978f1cf26cb4c1fc/vistagen-reports-fiscal-year-2025-second-quarter-financial-results-and-corporate-update 2024-11-07T21:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/b5b7238f28481fd6/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/d49c8d7cc77bd436/puma-biotechnology-reports-third-quarter-2024-financial-results-markets-data 2024-11-07T21:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/df5d9cc44e0ccd4a/profound-medical-announces-third-quarter-2024-financial-results-globenewswire 2024-11-07T21:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/7436ca994ad0b995/rocket-pharmaceuticals-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T21:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/d6a1365027f0a771/relmada-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-07T21:16:12+00:00 weekly 0.7 https://trial.medpath.com/news/aee443ca563f877c/iovance-biotherapeutics-reports-financial-results-and-globenewswire 2024-11-07T21:12:22+00:00 weekly 0.7 https://trial.medpath.com/news/19866f94d74bdd8d/senseonics-holdings-inc-reports-third-quarter-2024-financial-results-stock-titan 2024-11-07T21:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/b2e774db4517d969/lantern-pharma-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-07T21:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/557676438320a964/kura-oncology-reports-third-quarter-2024-financial-results 2024-11-07T21:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/36f1ed76c4421602/nkarta-reports-third-quarter-2024-financial-results-and-corporate-highlights 2024-11-07T21:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/6b82c326da684a1b/ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-07T21:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/e26646b1dfdb2efb/bioatla-reports-third-quarter-2024-financial-results-and-highlights-recent-progress 2024-11-07T21:03:07+00:00 weekly 0.7 https://trial.medpath.com/news/ad0669d9d7a2b64c/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/00083bef21d5b9d8/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T21:01:13+00:00 weekly 0.7 https://trial.medpath.com/news/7483b6a7de864d43/intravitreal-implant-could-transform-wet-amd-treatment-medpage-today 2024-11-07T20:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/bf5628c108cefb67/sarepta-scraps-a-duchenne-drug-as-gene-therapy-sales-rise-biopharma-dive 2024-11-07T20:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/8ed1df1d862d3eae/hope-biosciences-stem-cell-therapy-shows-promise-in-small-phase-2-trial 2024-11-07T20:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/047a02c751f5c839/fda-proposes-banning-oral-phenylephrine-in-decongestants-ny1 2024-11-07T20:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/00642601b77a01d1/amgen-aims-to-enter-glp-1-market-with-different-drug-approach-insidehealthpolicy-com 2024-11-07T20:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/7e727e7b46c97e60/late-breaking-clinical-data-and-real-world-evidence-presented-at-hiv-glasgow-as-gilead 2024-11-07T20:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/d8d9ca979ffb1108/a-clinical-trial-protocol-as-a-pointer-to-the-claimed-crystalline-form-of-a-compound-t-1152-21 2024-11-07T20:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/2fd69992d69f0551/new-car-t-cell-trial-launched-through-gates-institute-packages-two-cars-in-one-treatment 2024-11-07T20:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/327fcf27c8f7587b/new-dual-target-drug-shows-promise-against-bladder-cancer-jonathan-rosenberg 2024-11-07T20:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/4cc76edd9e9060a9/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-globenewswire 2024-11-07T19:47:59+00:00 weekly 0.7 https://trial.medpath.com/news/7f190d42f08ad739/curasight-a-s-publishes-clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients 2024-11-07T19:25:47+00:00 weekly 0.7 https://trial.medpath.com/news/e9a7c277b2c48d1d/fda-removes-clinical-holds-previously-placed-on-3-of-carsgen-s-oncology-cell-therapies 2024-11-07T19:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/0b535952080ef9ce/the-promise-of-personalized-neurostimulation-in-slowing-alzheimer-progression-neurology-live 2024-11-07T19:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/275ebb54f6a98b3b/fda-grants-type-c-meeting-to-discuss-paxalisib-pathways-in-glioblastoma 2024-11-07T19:06:23+00:00 weekly 0.7 https://trial.medpath.com/news/a9ec6d0f30ed3eb0/altimmune-announces-successful-completion-of-end-of-phase-2-globenewswire 2024-11-07T18:56:02+00:00 weekly 0.7 https://trial.medpath.com/news/f877509505c3642b/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/0d032f8a38907f0f/cofactor-genomics-publishes-clinical-validation-of-oncoprism-hnscc-a-test-leveraging 2024-11-07T18:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/8b69fd4c40157689/marvel-biosciences-announces-mb204-outperforms-approved-drug-trofinetide-in-a-biospace 2024-11-07T18:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/6d4f6591238566a1/trauma-patients-could-be-enrolled-without-consent-in-study-of-drugs-to-prevent-blood-loss 2024-11-07T18:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/70c2a683ef5bea03/sarepta-pulls-plug-on-duchenne-exon-skipping-drug-pharmaphorum 2024-11-07T18:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/0a8f5208ad118a45/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T18:18:35+00:00 weekly 0.7 https://trial.medpath.com/news/89f1d28227c76ced/assessing-phase-2-data-on-bepranemab-s-effect-on-tau-accumulation-and-cognitive-function 2024-11-07T18:10:43+00:00 weekly 0.7 https://trial.medpath.com/news/b8e2ae45bb3b60d9/kwality-pharma-received-approval-for-leuprorelin-acetate-for-injectable-suspension-from-greece 2024-11-07T17:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/f1ad3a0409897665/phase-iii-align-trial-shows-atrasentan-significantly-reduces-proteinuria-in-high-risk-iga 2024-11-07T17:38:56+00:00 weekly 0.7 https://trial.medpath.com/news/85f6bdef9b4e46d0/ema-accepts-marketing-authorization-application-for-alvotech-s-avt05-golimumab 2024-11-07T17:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/e0e6d979f305343b/review-clinical-trials-show-cannabis-improves-symptoms-in-fibromyalgia-patients 2024-11-07T17:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/9317963d224d8320/fda-suggests-removing-oral-phenylephrine-as-otc-monograph-nasal-decongestant-ingredient 2024-11-07T17:23:16+00:00 weekly 0.7 https://trial.medpath.com/news/addbeb24cd5fc786/parkinson-s-disease-clinical-research-in-7mm-focuses-on-disease-modifying-agents 2024-11-07T17:19:44+00:00 weekly 0.7 https://trial.medpath.com/news/ff310a86aad5ddb9/study-explores-underpinnings-of-immunotherapy-releated-myocarditis-in-patients-with-cancer 2024-11-07T17:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/bc647935036f471e/j-j-wins-fda-approval-for-varipulse-pfa-system-medtech-dive 2024-11-07T17:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/f2aec9cd9607ac7a/fda-grants-orphan-drug-designation-to-mb-108-for-malignant-glioma-onclive 2024-11-07T17:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/06d1bbcf0c6099da/minghui-pharmaceutical-s-mhb039a-shows-promise-in-phase-i-trial-for-solid-tumours 2024-11-07T16:53:42+00:00 weekly 0.7 https://trial.medpath.com/news/067ef06c2bd6fb0c/transgene-and-nec-present-new-data-confirming-clinical-globenewswire 2024-11-07T16:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/32795bf184d631b7/designing-inclusive-clinical-trials-in-an-effort-to-upend-the-hiv-epidemic-gilead-sciences 2024-11-07T16:42:05+00:00 weekly 0.7 https://trial.medpath.com/news/123507ed00fab520/emrosi-new-rosacea-treatment-option-approved-by-the-fda-webmd 2024-11-07T16:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/36992b4824f5ae66/sarepta-discontinues-next-generation-duchenne-drugs-stat-news 2024-11-07T16:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/c63e6a216f4b8329/padeliporfin-vtp-maintains-robust-responses-and-is-safe-in-low-grade-upper-tract 2024-11-07T16:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/5d3f38f9cbe85c18/senhwa-biosciences-starts-trial-of-silmitasertib-in-children-with-difficult-to-treat-cancers 2024-11-07T16:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/ee3be96a50578ae1/fda-places-clinical-hold-on-epilepsy-agent-rap-219-for-diabetic-peripheral-neuropathic-pain 2024-11-07T16:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/4ab8137ef1e65a71/eque-cel-car-t-shows-strong-results-for-multiple-myeloma 2024-11-07T16:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/5d3ed141da9cd2ef/phase-3-enlighted-trial-padeliporfin-vtp-shows-promise-in-low-grade-utuc 2024-11-07T16:03:26+00:00 weekly 0.7 https://trial.medpath.com/news/5fa4d56f6e4035ce/schizophrenia-pharmacology-version-2-0-psychiatric-times 2024-11-07T16:02:53+00:00 weekly 0.7 https://trial.medpath.com/news/6462cf54b330ba09/sitc-study-finds-io102-io103-vaccine-plus-pembrolizumab-active-in-patients-with-non 2024-11-07T15:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/19a7b3d050412740/springworks-therapeutics-announces-long-term-efficacy-and-safety-data-from-phase-3 2024-11-07T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/3fb53f9a2cb15292/postoperative-tumor-bed-radiation-versus-t-shaped-field-radiation-in-the-treatment-of-locally 2024-11-07T15:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/0061da298c7339e2/fda-approves-varipulse-platform-for-treatment-of-atrial-fibrillation-hcplive 2024-11-07T15:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/785366ececb77fa2/ema-approves-sanofi-regeneron-s-dupixent-for-young-eoe-patients-yahoo 2024-11-07T15:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/beba4bb1b48176d3/u-k-study-shows-most-cancer-patients-would-benefit-from-pharmacogenetic-testing 2024-11-07T15:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/daf5016081954ba0/uganda-phase-ii-of-mass-polio-vaccination-kicks-off-allafrica-com 2024-11-07T15:29:53+00:00 weekly 0.7 https://trial.medpath.com/news/562dfa8e30d01b61/sarepta-discontinues-development-of-duchenne-aso-treatment-vesleteplirsen 2024-11-07T15:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/6192943207d93c32/nektar-and-collaborators-present-late-breaking-results-from-phase-2-study-of-nktr-255 2024-11-07T15:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/7c49adf2ed783428/nimbus-therapeutics-presents-positive-updated-data-from-phase-1-2-clinical-trial-of-hpk1 2024-11-07T15:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/ce25e4e2b8809ffe/enfortumab-vedotin-plus-pembrolizumab-leads-to-shifts-in-frontline-metastatic-urothelial 2024-11-07T15:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/878233415392e2de/imunon-presents-positive-data-from-phase-2-ovation-2-globenewswire 2024-11-07T15:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/29e3822582c8fb6a/emergent-biosolutions-supports-new-clinical-trial-evaluating-the-safety-and-efficacy-biospace 2024-11-07T15:02:31+00:00 weekly 0.7 https://trial.medpath.com/news/cfe0f3bed8824acc/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T15:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/cacbb1fdc787cd37/vidac-pharma-receives-reinvestment-from-shareholders-to-drive-clinical-trials-of-its-cancer 2024-11-07T14:59:32+00:00 weekly 0.7 https://trial.medpath.com/news/5acea6877bae71bc/sarepta-halts-development-of-next-gen-dmd-drug-reports-robust-elevidys-sales 2024-11-07T14:58:05+00:00 weekly 0.7 https://trial.medpath.com/news/31f49c0c2e88d255/tacrolimus-linked-to-lower-acute-gvhd-risk-american-journal-of-managed-care 2024-11-07T14:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/9e20fe7d745ea193/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-biospace 2024-11-07T14:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/b9bb730aedfc8301/palvella-therapeutics-announces-first-patient-dosed-in-selva-phase-3-clinical-trial-biospace 2024-11-07T14:45:45+00:00 weekly 0.7 https://trial.medpath.com/news/c710b505473d3998/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T14:45:42+00:00 weekly 0.7 https://trial.medpath.com/news/1c1b8e49dd5ab23e/rallybio-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/4ce4517f36ace926/applied-therapeutics-reports-third-quarter-2024-financial-results-biospace 2024-11-07T14:45:05+00:00 weekly 0.7 https://trial.medpath.com/news/6d9b24a8c0f5a4ba/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-biospace 2024-11-07T14:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/f2efb8fa4fbe7823/pepgen-inc-sec-10-q-report-tradingview 2024-11-07T14:43:51+00:00 weekly 0.7 https://trial.medpath.com/news/29fa9becf96d3a4f/pmv-pharmaceuticals-inc-sec-10-q-report-tradingview 2024-11-07T14:43:05+00:00 weekly 0.7 https://trial.medpath.com/news/6f743ba6d295882d/fda-grants-orphan-drug-designation-to-lbl-034-in-multiple-myeloma-targeted-oncology 2024-11-07T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/2e030bb18537ed17/fda-to-decide-on-spn-830-apomorphine-pump-approval-feb-1-parkinson-s-news-today 2024-11-07T14:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/9e8fbfb0464f61fd/pharmala-to-supply-laneo-mdma-for-clinical-trial-at-yale-globenewswire 2024-11-07T14:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/ec120903031f82ca/ryvu-therapeutics-reports-2024-q3-financial-results-and-provides-corporate-update 2024-11-07T14:31:18+00:00 weekly 0.7 https://trial.medpath.com/news/c9d7441efa397d5d/johnson-johnson-medtech-wins-fda-nod-for-varipulse-pfa-massdevice 2024-11-07T14:26:38+00:00 weekly 0.7 https://trial.medpath.com/news/7370a1d96cce55da/study-reveals-how-cancer-immunotherapy-leads-to-deadly-form-of-heart-inflammation-in 2024-11-07T14:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/ca7d015ab8d834dd/rome-therapeutics-to-present-data-supporting-line-1-reverse-transcriptase-inhibitors-as 2024-11-07T14:19:32+00:00 weekly 0.7 https://trial.medpath.com/news/61abbfcbb4f67658/addressing-informative-censoring-bias-in-clinical-trials-targeted-oncology 2024-11-07T14:07:43+00:00 weekly 0.7 https://trial.medpath.com/news/4a0edc25bd0e65e3/adipo-therapeutics-presents-positive-study-results-about-potential-obesity-treatment-news 2024-11-07T14:01:15+00:00 weekly 0.7 https://trial.medpath.com/news/959f810b8f19af07/oculis-reports-q3-2024-financial-results-and-provides-company-updates-markets-insider 2024-11-07T13:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/94e38e53ba2cbdcf/how-improvements-in-us-fda-regulatory-process-and-procedures-led-to-the-drug-approval 2024-11-07T13:58:24+00:00 weekly 0.7 https://trial.medpath.com/news/b4e533bac5ceed50/driving-pan-african-research-collaboration-panther-and-africa-cdc-launch-the-mpox 2024-11-07T13:52:55+00:00 weekly 0.7 https://trial.medpath.com/news/f7a80a1f2c962194/mustang-bio-granted-orphan-drug-designation-by-u-s-fda-for-mb-108-hsv-1-oncolytic 2024-11-07T13:51:35+00:00 weekly 0.7 https://trial.medpath.com/news/6cd479112a493fd2/palisade-bio-launches-phase-1-trial-for-novel-ulcerative-colitis-drug-pali-2108 2024-11-07T13:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/b85aea0b17155131/cassava-sciences-nears-alzheimer-s-drug-trial-results-investing-com 2024-11-07T13:38:58+00:00 weekly 0.7 https://trial.medpath.com/news/73c7b58c0c553954/gilead-beats-q3-expectations-fueled-by-hiv-drug-sales-raises-full-year-guidance 2024-11-07T13:37:08+00:00 weekly 0.7 https://trial.medpath.com/news/2734728258f51786/q32-bio-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T13:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/556e2b28296dbe57/cancer-antibody-drug-conjugates-market-drugs-approval-price-sales-clinical-trials 2024-11-07T13:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/b091fbfb621bd0cb/lung-cancer-awareness-month-2024-looking-back-at-progress-for-cell-and-gene-therapy 2024-11-07T13:20:21+00:00 weekly 0.7 https://trial.medpath.com/news/c70278b5505b3b39/lakeshore-biopharma-initiates-biologics-license-application-of-pika-rabies-vaccine-to-the 2024-11-07T13:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/7522edaf46e05357/quoin-pharmaceuticals-provides-corporate-update-and-announces-third-quarter-2024 2024-11-07T13:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/1b70ff643ca21adb/cel-sci-s-cancer-drug-shows-73-survival-rate-fda-agrees-on-pd-l1-biomarker-use 2024-11-07T13:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/e6f107c023b6886b/rome-therapeutics-to-present-data-supporting-line-1-reverse-globenewswire 2024-11-07T13:12:32+00:00 weekly 0.7 https://trial.medpath.com/news/3f294052bb94d9ea/magea4-opens-the-door-for-engineered-cellular-therapies-in-solid-tumors-onclive 2024-11-07T13:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/105330a4f22921af/imunon-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-07T13:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/77844a851b9a8b9c/johnson-johnson-medtech-receives-fda-approval-for-the-varipulsetm-pulsed-field 2024-11-07T13:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/a8ba99f14d48c368/movano-health-announces-completion-of-clinical-study-with-cuffless-rf-blood-pressure-device 2024-11-07T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/b874988478fb1058/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/c4bbba5f67b33e93/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:47:47+00:00 weekly 0.7 https://trial.medpath.com/news/53075d5fc89e9e3a/castle-boasts-melanoma-test-s-capacity-to-reduce-unnecessary-testing-clinical-trials-arena 2024-11-07T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/5fd1582884b0d9e1/moonlake-immunotherapeutics-sec-10-q-report-tradingview 2024-11-07T12:40:33+00:00 weekly 0.7 https://trial.medpath.com/news/8d15543dba3cd0b1/olanzapine-for-young-people-with-anorexia-nervosa-open-results-of-a-feasibility-study 2024-11-07T12:40:28+00:00 weekly 0.7 https://trial.medpath.com/news/66fa9cfbe34b47b8/xoma-royalty-reports-third-quarter-2024-financial-results-and-highlights-recent-activities 2024-11-07T12:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/03aa9c86af732418/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-mondaq 2024-11-07T12:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/b5142efd9f37439d/sanofi-regeneron-s-dupixent-approved-by-ec-for-younger-eosinophilic-oesophagitis-patients 2024-11-07T12:27:18+00:00 weekly 0.7 https://trial.medpath.com/news/6a75f8fa5241613a/eton-pharmaceuticals-awarded-second-patent-for-et-400-hydrocortisone-oral-solution 2024-11-07T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/fe6ab35d354e71cd/amylyx-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-07T12:21:15+00:00 weekly 0.7 https://trial.medpath.com/news/78752125500210fc/astrazeneca-showcases-strength-of-hematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T12:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/ed15bf7c9d3df0d7/eu-approves-dupixent-for-treating-eosinophilic-esophagitis-in-young-children 2024-11-07T12:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/220a957049192d92/impact-biotech-presents-updated-interim-phase-3-data-from-enlighted-study-of-morningstar 2024-11-07T12:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/628a9b57e1707182/impact-biotech-presents-updated-interim-phase-3-data-from-globenewswire 2024-11-07T12:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/fa8ef28985f92724/rapport-therapeutics-reports-third-quarter-financials-and-provides-business-update 2024-11-07T12:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/7542de1df7f00af7/applied-therapeutics-reports-third-quarter-2024-financial-results-globenewswire 2024-11-07T12:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/c9c5ff0fccf47da3/drug-giants-display-advanced-technologies-solutions-at-ciie-chinadaily-com-cn 2024-11-07T11:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/13e004d1a2767b5a/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:39:59+00:00 weekly 0.7 https://trial.medpath.com/news/9dd8617e59b8d2ed/immunic-inc-reports-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-07T11:36:16+00:00 weekly 0.7 https://trial.medpath.com/news/4241ad6507b00a59/ocugen-secures-30-million-in-debt-funding-globenewswire 2024-11-07T11:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/cf7ea532c47619b6/arbutus-biopharma-corp-abus-q3-2024-earnings-call-highlights-promising-clinical-trials-and 2024-11-07T11:33:19+00:00 weekly 0.7 https://trial.medpath.com/news/3a786ccd51086e32/senhwa-enrols-first-subject-in-phase-i-ii-trial-of-silmitasertib-for-solid-tumours 2024-11-07T11:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/a88f3ba7426f0f73/cerebral-near-infrared-spectroscopy-guided-neonatal-intensive-care-management-for-the-nature 2024-11-07T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/cc068cb9c745c076/using-abortion-pills-very-early-in-pregnancy-is-safe-study-finds 2024-11-07T11:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/3640ccc6aaab72f1/psilocybin-shows-effectiveness-in-curbing-anorexia 2024-11-07T11:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/b26a7a3d6c7bb9eb/new-wave-of-trials-in-huntington-s-disease-bring-hope-to-the-neurology-today 2024-11-07T11:00:46+00:00 weekly 0.7 https://trial.medpath.com/news/a9a80ccf4061f824/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:46:04+00:00 weekly 0.7 https://trial.medpath.com/news/ad2c880fb70c0001/qutenza-r-phase-iii-clinical-trial-for-post-surgical-neuropathic-pain-successfully-enrolls 2024-11-07T10:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/b3b1246ae0be0d9f/sanofi-regeneron-dupixent-approved-in-eu-for-young-children-with-eosinophilic-esophagitis 2024-11-07T10:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/5740ee02461ce14c/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy-yahoo-finance 2024-11-07T10:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/96ffe4903bd48e83/cumberland-pharmaceuticals-receives-fda-orphan-drug-and-rare 2024-11-07T10:22:18+00:00 weekly 0.7 https://trial.medpath.com/news/52796c4d4618819d/ionis-announces-design-for-phase-iii-trial-of-angelman-syndrome-therapy 2024-11-07T10:21:34+00:00 weekly 0.7 https://trial.medpath.com/news/305bf2af771dbc2c/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T10:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/562675d6d8f0aabd/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical-trial-with 2024-11-07T10:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/7639c0ce203c93dd/inquis-raises-40m-for-pivotal-trial-of-clot-removal-device 2024-11-07T10:02:00+00:00 weekly 0.7 https://trial.medpath.com/news/72b884e56d542ca6/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/2a512b3d836ab6ec/alzheimer-s-drug-used-to-reduce-brain-damage-may-triple-death-risk-study-news18 2024-11-07T09:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/6d41273c75611ad9/emergent-biosolutions-supports-new-clinical-trial-globenewswire 2024-11-07T09:51:10+00:00 weekly 0.7 https://trial.medpath.com/news/bf3c62615d3e9e40/ema-approves-dupixent-for-young-eoe-patients-pharmaceutical-technology 2024-11-07T09:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/3e0aff5d1acc244e/grunenthal-and-averitas-pharma-announce-completion-of-recruitment-for-phase-iii-clinical 2024-11-07T09:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/94e96a30d8f2711d/maat-pharma-to-present-updates-from-early-access-program-at-the-2024-ash-annual 2024-11-07T09:44:21+00:00 weekly 0.7 https://trial.medpath.com/news/a91c2fc5afb332da/oculis-reports-q3-2024-financial-results-and-provides-company-updates 2024-11-07T09:18:45+00:00 weekly 0.7 https://trial.medpath.com/news/0436d81eea15bc0f/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-07T08:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/475862f1735935de/ema-approves-dupixent-to-treat-eosinophilic-esophagitis-in-children-as-young-as-one-year 2024-11-07T08:30:10+00:00 weekly 0.7 https://trial.medpath.com/news/1b4e7f0977ca0562/next-generation-trk-inhibitors-show-promise-in-treating-ntrk-fusion-positive-cancers 2024-11-07T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/1644d9628865c1a9/roche-to-present-more-than-40-abstracts-across-nine-blood-disorders-at-the-66th-ash-meeting 2024-11-07T07:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/b5a37d3d695559fb/astrazeneca-showcases-strength-of-haematology-portfolio-and-pipeline-at-ash-2024 2024-11-07T07:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/28b3dda6c6e093e5/ultimovacs-asa-fra-7um-q3-2024-earnings-call-highlights-strat-gurufocus 2024-11-07T07:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/c8e2d31a027f0131/uk-s-vpag-scheme-launches-new-metrics-framework-to-track-pharmaceutical-access-and-pricing 2024-11-07T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/51b5cb9ffe0fbc54/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-07T06:43:21+00:00 weekly 0.7 https://trial.medpath.com/news/20db44a66297f115/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-07T06:42:56+00:00 weekly 0.7 https://trial.medpath.com/news/df8a2828284b3f22/cellectar-to-present-new-phase-2-data-on-iopofosine-i-131-for-waldenstroms-macroglobulinemia-at-ash-2024 2024-11-07T06:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/85acae70e45f5883/doctors-in-australia-lead-phase-3-theranostics-study-targeting-advanced-prostate-cancer 2024-11-07T06:39:39+00:00 weekly 0.7 https://trial.medpath.com/news/090f961dacf39da8/clinical-phase-ii-trial-of-upar-pet-in-brain-cancer-patients-published-cision-news 2024-11-07T06:08:25+00:00 weekly 0.7 https://trial.medpath.com/news/a50b66f89cc322e2/scope-of-things-scope-europe-2024-ai-in-clinical-trials-rising-stars-more 2024-11-07T06:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/a12fcede35c8898b/adopting-broader-clinical-trial-eligibility-in-lung-cancer-with-brain-mets-leptomeningeal-disease 2024-11-07T05:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/c196e181d2bef8a6/nccn-expands-genetic-testing-guidelines-to-include-prostate-cancer-and-updates-multi-cancer-risk-assessment 2024-11-07T05:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/e54ac0901288b297/advanced-hemophilia-treatments-show-promise-for-joint-health-while-access-barriers-persist-globally 2024-11-07T05:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d6ec53898bc2bb6/urogen-pharma-reports-q3-results-and-drug-progress-tipranks-com 2024-11-07T05:14:35+00:00 weekly 0.7 https://trial.medpath.com/news/32d9ecc164c27cd9/rna-editing-promises-to-go-where-dna-editing-can-t-the-hindu 2024-11-07T04:54:59+00:00 weekly 0.7 https://trial.medpath.com/news/ce360eb43a53eef8/alcon-s-digital-transformation-success-clinical-trial-platform-drives-35-faster-database-delivery 2024-11-07T04:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/e84d7e96de748d15/case-study-suggests-some-men-with-advanced-prostate-cancer-could-benefit-from-t-dxd 2024-11-07T04:32:05+00:00 weekly 0.7 https://trial.medpath.com/news/e840ecf1c9e75711/cyramza-tagrisso-combo-prolongs-pfs-in-some-patients-with-nsclc-subset-cure-today 2024-11-07T04:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/d3472bba12df13e3/medicare-drug-price-negotiations-face-uncertain-future-under-potential-trump-administration 2024-11-07T03:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/ef980015da50669d/askbio-receives-fda-rare-pediatric-disease-and-orphan-drug-designations-for-ab-1003-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-r9 2024-11-07T03:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/a8ba0678ba447855/q-a-botox-cosmetic-s-fda-approval-may-lead-to-higher-visibility-more-patient-inquiries 2024-11-07T03:09:14+00:00 weekly 0.7 https://trial.medpath.com/news/9d51da3b88bcba59/grand-rounds-november-22-2024-tranexamic-acid-in-patients-undergoing-liver-resection 2024-11-07T02:45:58+00:00 weekly 0.7 https://trial.medpath.com/news/f9ce0b4a24ed05f6/radiotherapy-manchester-scientists-use-ai-to-simulate-cancer-patient-trials-bbc 2024-11-07T02:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/94c41a0a2a7fe5c5/implementing-palliative-care-in-hepatocellular-carcinoma-ambulatory-clinics-study-protocol-trials 2024-11-07T02:30:15+00:00 weekly 0.7 https://trial.medpath.com/news/761fd7c26e737559/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-cision-news 2024-11-07T01:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/b566d69e5fb4524d/long-term-data-support-efficacy-safety-of-new-schizophrenia-drug-medpage-today 2024-11-07T01:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/2a42729acc3ba55f/seastar-medical-s-scd-wins-4th-fda-breakthrough-status-targets-48b-dialysis-market 2024-11-07T01:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/2c5ba53def4273f2/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-07T01:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/c163b3720946fb88/soleno-therapeutics-inc-sec-10-q-report-tradingview 2024-11-07T00:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/2537e782d9794906/blackstone-s-proposed-acquisition-of-i-rom-raises-concerns-accc 2024-11-07T00:34:44+00:00 weekly 0.7 https://trial.medpath.com/news/53862aa047c85c62/huidagene-therapeutics-crispr-cas13-rna-editing-therapy-hg202-gets-cgtlive-r 2024-11-07T00:21:47+00:00 weekly 0.7 https://trial.medpath.com/news/3c66a08fbed2ce50/jama-oncology-publishes-phase-1b-2-study-data-on-iaso-bio-s-equecabtagene-autoleucel-fucasotm-in-the-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-07T00:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/985b729aeb747878/pds-biotech-interview-with-president-and-ceo-frank-bedu-addo-about-the 2024-11-07T00:04:24+00:00 weekly 0.7 https://trial.medpath.com/news/fc178634cbc81214/north-texas-caris-life-sciences-gets-fda-approval-for-its-mi-cancer-seek-companion 2024-11-07T00:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/43be6079c2194cc6/cancer-drug-discovery-news 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/45260ec4f6521e0c/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2024-11-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/5ca7b81b56d0b142/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T23:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/28a6ecce4cdae406/elan-stock-report-elanco-animal-health-investors-are-globenewswire 2024-11-06T23:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/d22dfeab5a0dd69b/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-biospace 2024-11-06T23:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/39a0325787287b22/johnson-johnson-s-shockwave-medical-shares-first-clinical-outcomes-associated-with 2024-11-06T23:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/911a9af9329eefcc/severe-asthma-clinical-trial-pipeline-appears-robust-with-40-key-pharma-companies 2024-11-06T22:45:13+00:00 weekly 0.7 https://trial.medpath.com/news/69dadb117daf48e0/sab-bio-announces-third-quarter-2024-financial-results-and-provides-company-update 2024-11-06T22:18:42+00:00 weekly 0.7 https://trial.medpath.com/news/232c0a24b67c6e28/brightspring-s-caremed-tapped-for-breakthrough-alzheimer-s-drug-leqembi-distribution 2024-11-06T22:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/58a726a5e2771424/sarepta-therapeutics-inc-sec-10-q-report-tradingview 2024-11-06T21:38:57+00:00 weekly 0.7 https://trial.medpath.com/news/d01c10fae2c2c108/lytix-biopharma-first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo 2024-11-06T21:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/e0ea005db3757058/arcutis-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T21:26:08+00:00 weekly 0.7 https://trial.medpath.com/news/cb60ec46882449d2/vanda-pharmaceuticals-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T21:20:36+00:00 weekly 0.7 https://trial.medpath.com/news/652f594426abfe96/regenxbio-reports-third-quarter-2024-financial-results-and-recent-operational-updates 2024-11-06T21:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/3e4543872b10e5e2/soleno-therapeutics-provides-corporate-update-and-reports-third-quarter-2024-financial-results 2024-11-06T21:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/fed7afe2268c8dda/nyxoah-reports-third-quarter-financial-and-operating-results-stock-titan 2024-11-06T21:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/bd6ba983f18b22e5/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-the-manila-times 2024-11-06T21:15:43+00:00 weekly 0.7 https://trial.medpath.com/news/9244463c2abc3cf0/adicet-reports-third-quarter-2024-financial-results-and-provides-business-updates 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/bc4de4e711187101/verastem-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T21:15:38+00:00 weekly 0.7 https://trial.medpath.com/news/4debba9da1770947/top-in-endocrinology-sotagliflozin-rejected-by-fda-new-lifestyle-intervention-guidelines 2024-11-06T21:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/eff4e2d8658796a1/aurobindo-obtains-fda-ok-for-generic-keflet-drug-store-news 2024-11-06T21:13:39+00:00 weekly 0.7 https://trial.medpath.com/news/6d893369e2b22ca5/phase-3-data-shows-lumateperone-delays-schizophrenia-relapse-longer-than-placebo 2024-11-06T21:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/f5ef0ab0a873a1f4/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-globenewswire 2024-11-06T21:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/3fef3740f4fd5333/a-first-in-human-open-label-phase-ia-ib-multicenter-multiregional-dose-escalation-study 2024-11-06T21:00:13+00:00 weekly 0.7 https://trial.medpath.com/news/871e6b399e12d389/update-predicinecaretm-liquid-biopsy-assay-featured-in-nejm-for-patient-enrollment-in 2024-11-06T20:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/e6d3e395ae98094f/corin-announces-fda-510-k-clearance-for-new-iconatm-femoral-stem-ortho-spine-news 2024-11-06T20:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/d635a0af03732ba7/merck-and-moderna-launch-phase-3-trial-for-mrna-4157-neoantigen-therapy-plus 2024-11-06T20:51:22+00:00 weekly 0.7 https://trial.medpath.com/news/900870b52e20996f/japan-s-national-cancer-center-selects-paradigm-for-nationwide-clinical-trial-network 2024-11-06T20:37:16+00:00 weekly 0.7 https://trial.medpath.com/news/623d4c6570b0e932/fda-approval-withdrawal-of-trodelvy-leaves-fewer-bladder-cancer-options-cure-today 2024-11-06T20:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/239d11342f60a0ad/around-the-helix-cell-and-gene-therapy-company-updates-november-6-2024 2024-11-06T20:12:25+00:00 weekly 0.7 https://trial.medpath.com/news/d16581271048f108/a-diabetes-drug-twice-rejected-stumbles-again-but-its-developer-persists-pharmavoice 2024-11-06T20:04:19+00:00 weekly 0.7 https://trial.medpath.com/news/f7741d59bcc5db0f/platelet-counts-may-predict-long-term-ultomiris-response-in-ahus-study 2024-11-06T19:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/a5d727bef2bf94c0/cassava-s-alzheimer-s-drug-nears-p3-readout-but-sec-scandal-casts-long-shadow 2024-11-06T19:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/723bd4483568794e/a-36-gene-predictive-score-of-anti-cancer-drug-resistance-anticipates-cancer-therapy-outcomes 2024-11-06T19:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/8200b57a8db69a28/earnings-call-cellectis-reports-robust-cash-reserves-new-r-d-initiatives-investing-com 2024-11-06T19:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/9cf8213e55df5d9b/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-pharmaceutical-technology 2024-11-06T19:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/05ee361b2eb66d13/nasal-swab-might-predict-how-severe-covid-will-be 2024-11-06T19:00:59+00:00 weekly 0.7 https://trial.medpath.com/news/6e4b6b7a9712c75b/earnings-call-rhythm-pharmaceuticals-has-reported-a-successful-third-quarter-in-2024 2024-11-06T18:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/e6983e3a3040846a/study-to-assess-performance-of-cxbladder-test-in-urothelial-carcinoma-surveillance 2024-11-06T18:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/4bc5248401995f48/ac102-shows-promise-as-treatment-for-sudden-hearing-loss 2024-11-06T18:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/24cbbc08ff0ad753/canada-s-pharma-pipeline-expands-with-12000-new-medicines-as-oncology-leads-trials 2024-11-06T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/news/d994aaacb1347843/first-patient-dosed-in-ankyra-s-visceral-tumour-study-of-ank-101-clinical-trials-arena 2024-11-06T18:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/29ec605efb12592e/milestone-as-pregnant-women-included-in-sa-tb-drug-trial-juta-medicalbrief 2024-11-06T18:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/cde082aeb159b018/tetanus-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-11-06T18:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/ae67ef99000b2ba4/qiagen-s-qiastat-dx-meningitis-encephalitis-panel-gains-fda-clearance-for-rapid 2024-11-06T18:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/e49969fa0f06f1a4/sa-women-could-have-three-monthly-anti-hiv-ring-by-2026-juta-medicalbrief 2024-11-06T17:50:22+00:00 weekly 0.7 https://trial.medpath.com/news/314e2f24579db872/national-institute-on-aging-invests-an-additional-7-3-million-into-nu-9-northwestern-now 2024-11-06T17:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/4d35590b92ec05ce/dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young-children-with-pipelinereview 2024-11-06T17:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/e89aae8feb3570e3/fda-approves-new-oral-drug-for-utis-despite-concerns-juta-medicalbrief 2024-11-06T17:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/b0687c6bb6cbd124/positive-phase-3-results-evaluating-lumateperone-for-the-prevention-of-relapse-in-schizophrenia 2024-11-06T17:17:29+00:00 weekly 0.7 https://trial.medpath.com/news/ae927af978a674b2/study-raises-hopes-of-treating-aggressive-cancers-by-zapping-rogue-dna-the-guardian 2024-11-06T17:15:20+00:00 weekly 0.7 https://trial.medpath.com/news/e697bdd26e684869/the-value-of-a-negative-result-uc-davis-health 2024-11-06T17:12:46+00:00 weekly 0.7 https://trial.medpath.com/news/0b7a226997c50c55/fda-clears-phase-2-trial-of-leronlimab-for-microsatellite-stable-crc-targeted-oncology 2024-11-06T17:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/1df742c8e55d34aa/fda-pushes-pdufa-date-of-tapinarof-cream-1-for-atopic-dermatitis-to-2025 2024-11-06T17:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/b0a8ef50b1dce154/fda-accepts-bla-for-denosumab-biosimilar-hcplive 2024-11-06T17:11:15+00:00 weekly 0.7 https://trial.medpath.com/news/cc938c20b34db3d1/no-benefit-for-extended-lymph-node-surgery-in-mibc-national-cancer-institute 2024-11-06T17:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/7573f067090f5e4d/domvanalimab-combo-improves-survival-in-advanced-metastatic-nsclc-cancer-network 2024-11-06T17:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/6fa8825b9e83a5c7/reviva-to-present-positive-speech-latency-data-for-brilaroxazine-in-schizophrenia-from-the 2024-11-06T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/3bd0d414211cd3e1/cytodyn-gets-us-fda-nod-to-begin-phase-ii-oncology-trial-of-leronlimab-in-patients-with-r-r 2024-11-06T17:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/4d8f893013133c13/fda-grants-orphan-drug-designation-to-lbl-034-for-multiple-myeloma-onclive 2024-11-06T16:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/4b0214bba0c94ece/mi-cancer-seek-receives-fda-approval-as-companion-diagnostic-for-targeted-therapy 2024-11-06T16:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/0e1386d02376f094/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:48:50+00:00 weekly 0.7 https://trial.medpath.com/news/4989ad5cf94696e2/fda-grants-market-authorization-to-light-therapy-system-for-dry-amd-medpage-today 2024-11-06T16:40:45+00:00 weekly 0.7 https://trial.medpath.com/news/706ba855b15297df/moderna-said-to-shuffle-sales-leadership-vertex-records-first-casgevy-sale 2024-11-06T16:38:32+00:00 weekly 0.7 https://trial.medpath.com/news/38ba6f9cba4fe419/fidanacogene-elaparvovec-shows-strong-results-in-open-label-phase-3-study 2024-11-06T16:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/86bbd041efd3adb1/lumithera-s-valeda-light-delivery-system-receives-marketing-authorization-from-fda 2024-11-06T16:26:50+00:00 weekly 0.7 https://trial.medpath.com/news/f5f4cd354caf5569/caris-life-sciences-nabs-fda-approval-for-multicancer-companion-diagnostic 2024-11-06T16:19:04+00:00 weekly 0.7 https://trial.medpath.com/news/33188f66b1d9fe87/fda-renews-approval-for-jaguar-s-cid-treatment-in-dogs-investing-com 2024-11-06T16:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/3c9e08b394496979/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T16:14:36+00:00 weekly 0.7 https://trial.medpath.com/news/276b3beb1772c89b/once-weekly-semaglutide-reduces-knee-osteoarthritis-pain-body-weight-in-patients-with 2024-11-06T16:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/145cecab7854b4d6/t-cell-lymphoma-pipeline-insight-analysis-report-2024-globenewswire 2024-11-06T16:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/20c44510ceb80ca9/cracking-the-code-of-dna-circles-in-cancer-stanford-medicine-led-team-uncovers-potential-therapy 2024-11-06T16:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/bc2d4fed91118787/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/f4bf091f25ad4032/inhibiting-viral-rna-cap-methylation-with-anti-viral-molecules-news-medical 2024-11-06T15:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/34eb4b9635d2640c/senhwa-biosciences-announces-first-patient-dosed-in-the-phase-i-ii-study-of-silmitasertib-in 2024-11-06T15:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/1417f6624773caed/precision-medicine-in-sclc-key-biomarkers-revealed-mirage-news 2024-11-06T15:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/125258d745d34d0f/addition-of-atezolizumab-plus-bevacizumab-to-chemotherapy-in-advanced-biliary-tract-cancer 2024-11-06T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/f3bf103f33abdf8b/fda-approves-renewal-of-canalevia-ca1-jaguar-health-s-drug-for-chemotherapy-stock-titan 2024-11-06T15:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/ba7b44a7254c9ac4/diamyd-medical-to-present-new-analytical-results-at-diabetes-congress-marketscreener 2024-11-06T15:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/0bde2b7cd9f298da/next-generation-oral-serd-in-postmenopausal-women-with-er-positive-her2-negative 2024-11-06T15:13:55+00:00 weekly 0.7 https://trial.medpath.com/news/011046c635612698/lundbeck-to-acquire-longboard-drug-store-news 2024-11-06T15:13:36+00:00 weekly 0.7 https://trial.medpath.com/news/396988e18da52e47/zymeworks-doses-first-subject-in-phase-i-trial-of-zw191-for-solid-tumours 2024-11-06T15:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/1763af899ae59903/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T15:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/016ab6bf570680bf/dementia-combo-of-2-active-therapies-may-slow-cognitive-decline 2024-11-06T14:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/eb4747252aeb0f2f/recce-pharmaceuticals-advances-patient-dosing-to-final-stages-in-phase-ii-trial-for-acute 2024-11-06T14:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/10cfaab2420574d2/startup-gives-surgeons-a-real-time-view-of-breast-cancer-during-surgery-mit-news 2024-11-06T14:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/4cb152bad9385bf7/fda-grants-breakthrough-status-to-seastar-medical-s-scd-investing-com 2024-11-06T14:18:09+00:00 weekly 0.7 https://trial.medpath.com/news/e1339f7317d1f189/first-of-a-kind-eu-approval-granted-for-eosinophilic-esophagitis-medicine 2024-11-06T14:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/f4390655d791bf54/patient-dies-in-beam-trial-of-scd-candidate-company-cites-conditioning 2024-11-06T14:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/982c614804a3a2ac/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-pr-newswire 2024-11-06T14:11:43+00:00 weekly 0.7 https://trial.medpath.com/news/630895885af13c04/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win-clinical-trials-arena 2024-11-06T14:10:50+00:00 weekly 0.7 https://trial.medpath.com/news/63acef2a4889db4c/fda-grants-breakthrough-device-designation-for-seastar-globenewswire 2024-11-06T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/6dedb8a5b65fa66a/zollinger-ellison-syndrome-gastrinoma-global-clinical-trials-review-2024-yahoo-finance 2024-11-06T14:03:42+00:00 weekly 0.7 https://trial.medpath.com/news/b968ad2af515ab65/zollinger-ellison-syndrome-gastrinoma-global-clinical-globenewswire 2024-11-06T13:58:38+00:00 weekly 0.7 https://trial.medpath.com/news/b299a51189fb1858/ionis-reports-third-quarter-2024-financial-results-company-announcement-ft-com 2024-11-06T13:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/a1b3ba7ae68466cf/pharma-firms-showcase-innovative-treatment-for-major-diseases-at-ciie-shine-news 2024-11-06T13:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/80b53c8cad6f4c4d/urogen-pharma-reports-2024-third-quarter-financial-results-and-business-highlights 2024-11-06T13:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/cbd9796466b144f3/promising-use-of-lytix-cancer-treatment-in-patients-with-early-stage-melanoma-finansavisen 2024-11-06T13:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/61d0b4d7850627dc/recce-pharmaceuticals-advances-patient-dosing-to-final-globenewswire 2024-11-06T13:23:20+00:00 weekly 0.7 https://trial.medpath.com/news/2d84fd3813356e9a/leal-raises-45m-to-advance-ltx-002-to-clinical-trials-for-als-als-news-today 2024-11-06T13:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/8c29425066554f83/reviva-to-present-positive-speech-latency-data-for-globenewswire 2024-11-06T13:17:08+00:00 weekly 0.7 https://trial.medpath.com/news/7c80a6d29df99a51/pds-biotech-to-announce-third-quarter-financial-results-on-globenewswire 2024-11-06T13:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/c1a2700146928ea5/uniqure-announces-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-06T13:15:41+00:00 weekly 0.7 https://trial.medpath.com/news/a9179179eaaaae1a/reviva-pharma-to-present-breakthrough-phase-3-schizophrenia-drug-data-at-cns-summit 2024-11-06T13:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/cdff76967b78763a/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T13:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/9300094a010c48c2/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-06T13:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/73b3255f2ff85fdd/phase-3-lugano-trial-explores-eyp-1901-s-potential-to-reduce-treatment-burden-in-wet 2024-11-06T13:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/4be1238bb321768f/ionis-reports-third-quarter-2024-financial-results-news-cnhinews-com 2024-11-06T13:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/1c21fcd9ec2dc0a4/phase-3-data-shows-tev-749-injection-improves-social-function-in-schizophrenia 2024-11-06T13:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/40bf8c90aa291f68/glycomimetics-announces-new-uproleselan-clinical-data-will-be-presented-at-ash-annual-meeting 2024-11-06T13:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/e3b7af2d27fe563b/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T13:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/a134bda5057a237d/first-patient-treated-in-new-phase-ii-clinical-trial-at-radiumhospitalet-in-oslo-tradingview 2024-11-06T12:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/70cf547ee78fcb97/praxis-precision-medicines-provides-corporate-update-and-reports-third-quarter-2024 2024-11-06T12:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/554cf2cdf9c3d50c/johnson-johnson-s-balversa-granted-mhra-approval-in-bladder-cancer-pmlive 2024-11-06T12:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/f5fd0d07b6607d15/fda-approves-journey-medical-s-emrosi-to-treat-inflammatory-lesions-of-rosacea-pmlive 2024-11-06T12:40:48+00:00 weekly 0.7 https://trial.medpath.com/news/e770cb1e5fb4b434/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/878dfc4583ffb163/update-to-the-statistical-analysis-plan-for-notacs-a-multicentre-adaptive-randomised-controlled-trial 2024-11-06T12:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/eea0990330191418/elevation-oncology-reports-third-quarter-2024-financial-results-and-highlights-recent 2024-11-06T12:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/e20626baa44436f2/praxis-precision-medicines-provides-corporate-update-and-globenewswire 2024-11-06T12:34:12+00:00 weekly 0.7 https://trial.medpath.com/news/fb72db5ffc8c7c57/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T12:33:00+00:00 weekly 0.7 https://trial.medpath.com/news/73ff521aed62edbe/ionis-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:32:59+00:00 weekly 0.7 https://trial.medpath.com/news/c7620afb1bad6550/ionis-reports-third-quarter-2024-financial-results-stock-titan 2024-11-06T12:19:06+00:00 weekly 0.7 https://trial.medpath.com/news/47fc950cb5876771/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T12:13:38+00:00 weekly 0.7 https://trial.medpath.com/news/24d3f9036b06503b/ionis-reports-third-quarter-2024-financial-results-placera 2024-11-06T12:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/49bf4602fd8f18c8/insignis-therapeutics-in-001-clinical-programme-receives-positive-fda-response 2024-11-06T12:08:59+00:00 weekly 0.7 https://trial.medpath.com/news/15793090ee55610c/lenz-therapeutics-reports-third-quarter-2024-financial-results-morningstar 2024-11-06T12:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/cdfe0e20ea8ba102/chinese-herbal-medicine-may-aid-dementia-prevention-mirage-news 2024-11-06T12:05:15+00:00 weekly 0.7 https://trial.medpath.com/news/8aa34f9c7a6a000b/ionis-announces-pivotal-phase-3-trial-design-for-ion582-in-angelman-syndrome 2024-11-06T12:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/88d8c027c84f67c1/ionis-reports-third-quarter-2024-financial-results-pr-newswire 2024-11-06T12:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/925563c4615800eb/imugene-bile-cancer-patient-maintains-full-response-mirage-news 2024-11-06T11:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/f279d700e7cab904/caris-life-sciences-receives-fda-approval-for-mi-cancer-seektm-as-a-companion 2024-11-06T11:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/89622850cfcb6578/mhra-grants-approval-for-bladder-cancer-drug-erdafitinib-pharmatimes 2024-11-06T11:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/e202be48663d8929/italy-tests-first-gene-edited-vines-for-winemaking-nature-biotechnology 2024-11-06T11:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/1f4569e0fc816677/new-trial-seeks-to-improve-ewing-sarcoma-treatment-outcomes-technology-networks 2024-11-06T11:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/91ddce8c3bfc7edc/gender-gap-persists-in-hematology-oncology-leadership-despite-growing-female-representation-in-medicine 2024-11-06T11:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/b89bc619616402e7/novo-nordisk-signs-deal-for-monthly-glp-1-agonist-european-biotechnology-magazine 2024-11-06T10:42:53+00:00 weekly 0.7 https://trial.medpath.com/news/7c78c3f9538d24f9/fda-clears-first-crispr-cas13-rna-editing-trial-for-macular-degeneration 2024-11-06T10:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/4c251244f31e2c2d/press-release-dupixent-approved-in-the-eu-as-the-first-and-only-medicine-for-young 2024-11-06T10:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/3e738f5c945c0b57/capsida-biotherapeutics-cap-003-displays-properties-of-disease-modification-in-cgtlive-r 2024-11-06T10:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/3eb686053da919ee/lumateperone-demonstrates-efficacy-in-reducing-symptomatic-relapse-risk-in-schizophrenia 2024-11-06T10:16:39+00:00 weekly 0.7 https://trial.medpath.com/news/9c5bd13ff33ccc43/minghui-pharmaceutical-announces-promising-initial-results-from-phase-i-clinical-trial-of 2024-11-06T10:04:14+00:00 weekly 0.7 https://trial.medpath.com/news/6b134ef10a61c4a5/eu-s-new-wastewater-treatment-directive-raises-concerns-over-generic-medicine-access 2024-11-06T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/52afeb055b942bd5/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-06T09:14:59+00:00 weekly 0.7 https://trial.medpath.com/news/2e1e5b36bc1647c0/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T09:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/448c39e8838cc691/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-06T09:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/e9149807b2c1e5ab/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of-biospace 2024-11-06T09:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/ac65ad647cc6ca5e/fda-roundup-november-5-2024-biospace 2024-11-06T09:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/7185f8b23828a36f/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-biospace 2024-11-06T09:14:52+00:00 weekly 0.7 https://trial.medpath.com/news/4cfbda3886dfe03c/update-on-fda-review-of-vtama-r-tapinarof-cream-1-for-the-treatment-of-atopic-biospace 2024-11-06T09:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/516cc35a3b1bd59a/protagonist-therapeutics-announces-poster-presentation-on-final-revive-phase-2-study 2024-11-06T09:14:48+00:00 weekly 0.7 https://trial.medpath.com/news/13473b95a1c46a31/gsk-s-rsv-vaccine-approved-in-canada-for-adults-aged-50-to-59 2024-11-06T09:05:09+00:00 weekly 0.7 https://trial.medpath.com/news/dcace454ba37d43b/vesper-bio-announces-successful-completion-of-phase-1-clinical-trial-for-ftd-grn-treatment 2024-11-06T09:00:15+00:00 weekly 0.7 https://trial.medpath.com/news/948b776d588bd3dd/jlk-receives-fda-approval-for-its-ai-stroke-diagnosis-solution-jlk-pwi-businesskorea 2024-11-06T08:55:54+00:00 weekly 0.7 https://trial.medpath.com/news/81457995e8b84030/dr-lotan-on-ongoing-research-with-novel-agents-in-bcg-unresponsive-nmibc-onclive 2024-11-06T08:47:10+00:00 weekly 0.7 https://trial.medpath.com/news/c8836ec0a447cdda/ruxolitinib-plus-pegylated-interferon-alfa-2a-is-safe-and-effective-in-in-newly-diagnosed-pv 2024-11-06T08:46:45+00:00 weekly 0.7 https://trial.medpath.com/news/a117a787a9b4d3a4/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-morningstar 2024-11-06T08:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/cef6487d076cc2b2/in-depth-analysis-showing-robust-diamyd-r-treatment-effects-across-clinical-trials-to-be 2024-11-06T08:13:26+00:00 weekly 0.7 https://trial.medpath.com/news/083f56ba25b91733/noninflammatory-neurotoxicity-events-in-patients-receiving-car-t-cgtlive-r 2024-11-06T07:06:55+00:00 weekly 0.7 https://trial.medpath.com/news/e3b81ae3053d6ea6/patient-death-reported-in-beam-scd-phase-i-ii-study-bioworld 2024-11-06T06:51:11+00:00 weekly 0.7 https://trial.medpath.com/news/00aafdaa5586c22e/igi-reports-75-response-rate-in-multiple-myeloma-drug-trial-the-hindu-businessline 2024-11-06T06:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/f79856f956109427/dupixent-r-dupilumab-approved-in-the-european-union-as-the-first-and-only-medicine-for 2024-11-06T06:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/36ea147dae81bdb0/ultimovacs-asa-reports-third-quarter-2024-financial-results-globenewswire 2024-11-06T06:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/8a43cbdf21c62041/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T06:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/9e4bede2b78dcb40/korean-aml-drug-shows-50-overall-complete-response-rate-in-p1-trial-kbr 2024-11-06T06:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/a2f45429d33fe0bb/press-release-dupixent-approved-in-the-eu-as-the-first-and-globenewswire 2024-11-06T06:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/d023231cf161cd10/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-06T05:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/c9fac70a2a53fe44/final-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-06T05:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/2a05b9989c9df485/rosacea-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-06T04:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/92a2fd1e84093b65/bostongene-advances-precision-oncology-with-ai-driven-molecular-profiling-research-at-major-cancer-symposiums 2024-11-06T04:34:35+00:00 weekly 0.7 https://trial.medpath.com/news/0923e9ba51a90971/hutchmed-highlights-clinical-data-to-be-presented-at-the-globenewswire 2024-11-06T04:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/8cde489663210486/cstone-pharmaceuticals-to-unveil-promising-lymphoma-drug-data-markets-insider 2024-11-06T03:55:37+00:00 weekly 0.7 https://trial.medpath.com/news/6c3eb505d2b5feac/acadia-pharmaceuticals-secures-150m-in-priority-review-voucher-sale-setting-high-benchmark 2024-11-06T03:35:00+00:00 weekly 0.7 https://trial.medpath.com/news/5b5c51677dee4a2d/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-06T03:24:05+00:00 weekly 0.7 https://trial.medpath.com/news/f9abf1435ff9cfed/fda-pushes-back-pdufa-date-3-months-for-tapinarof-1-cream-for-atopic-dermatitis-in 2024-11-06T02:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/7746bff667cddc11/fda-delays-decision-on-merus-bispecific-antibody-to-review-cmc-information-biospace 2024-11-06T02:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/12e0d5f4d0494506/research-grid-secures-6-5m-seed-funding-to-revolutionize-clinical-trial-efficiency-with-ai 2024-11-06T01:52:11+00:00 weekly 0.7 https://trial.medpath.com/news/ea87fe5e7b2854da/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:50:11+00:00 weekly 0.7 https://trial.medpath.com/news/020cf70013556795/antengene-to-present-results-from-two-late-stage-studies-of-selinexor-signaling-potential 2024-11-06T00:33:11+00:00 weekly 0.7 https://trial.medpath.com/news/7821f72620a368b3/nanoscope-therapeutics-retinitis-pigmentosa-gene-therapy-mco-010-improves-visual 2024-11-06T00:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/56242b059e414747/leads-biolabs-receives-orphan-drug-designation-from-the-us-fda-for-lbl-034-a-uniquely-designed-highly-differentiated-anti-gprc5d-cd3-bispecific-antibody-for-the-treatment-of-multiple-myeloma 2024-11-06T00:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/dfad6ea9195a72c8/how-hypoxia-helps-cancer-spread-johns-hopkins-medicine 2024-11-06T00:01:53+00:00 weekly 0.7 https://trial.medpath.com/news/338316b6a418ab9d/pp-007-receives-fda-fast-track-designation-for-treatment-of-acute-ischemic-stroke 2024-11-05T23:59:12+00:00 weekly 0.7 https://trial.medpath.com/news/4888ab9bd325bb34/implementation-of-the-new-european-health-technology-assessment-regulation-htar 2024-11-05T23:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/ac59c94c5cadf3f1/fda-approves-journey-s-rosacea-drug-eu-to-decide-on-novo-s-catalent-acquisition-by-6-december 2024-11-05T23:44:31+00:00 weekly 0.7 https://trial.medpath.com/news/da9e594a43136755/puma-biotechnology-launches-phase-ii-trial-of-alisertib-for-hr-positive-metastatic-breast-cancer 2024-11-05T23:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/009841044a2f3a8c/new-swiss-clinical-trial-framework-takes-effect-with-updated-reporting-rules-citeline 2024-11-05T22:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/f686902900d34048/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T22:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/dfda290ae5ba8e9a/anaptysbio-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/5ba447c1fd50c320/stoke-therapeutics-inc-sec-10-q-report-tradingview 2024-11-05T22:03:58+00:00 weekly 0.7 https://trial.medpath.com/news/91f68038adac419d/an-orally-bioavailable-gcn2-kinase-activator-for-the-treatment-of-clear-cell-renal-cell-carcinoma-and-acute-myeloid-leukemia 2024-11-05T21:53:39+00:00 weekly 0.7 https://trial.medpath.com/news/286d1ece28706c9e/new-drug-combo-shows-significant-promise-in-advanced-melanoma-trial 2024-11-05T21:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/c1d200ce783fc133/humacyte-s-atev-promising-clinical-performance-and-market-potential-drive-buy-rating 2024-11-05T21:25:41+00:00 weekly 0.7 https://trial.medpath.com/news/761d2cfdd8da5a60/anaptys-announces-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:18:07+00:00 weekly 0.7 https://trial.medpath.com/news/b45dd3aeb28b2808/poseida-to-unveil-breakthrough-cancer-therapy-data-at-sitc-ash-2024-conferences 2024-11-05T21:10:25+00:00 weekly 0.7 https://trial.medpath.com/news/a0d57a21c50adbde/syndax-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-05T21:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/882f50b79bdea5fa/ultragenyx-reports-third-quarter-2024-financial-results-and-corporate-update 2024-11-05T21:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/8c58d5f6a3eb16a6/fda-pushes-zenocutuzumab-decision-date-in-ngr1-nsclc-pdac-targeted-oncology 2024-11-05T20:49:42+00:00 weekly 0.7 https://trial.medpath.com/news/20a44cb20a91c8cc/fda-grants-de-novo-authorization-to-photobiomodulation-device-for-dry-amd-healio 2024-11-05T20:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/b3f27669f1ba2ee8/kite-to-highlight-industry-leading-car-t-cell-therapy-portfolio-at-ash-2024-including 2024-11-05T20:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/c3a660eb90fbbce6/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/b0399db3101deae4/highlights-in-prostate-cancer-treatment-advances-from-esmo-2024-ursula-vogl 2024-11-05T20:16:49+00:00 weekly 0.7 https://trial.medpath.com/news/4fa6688ef27cb908/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T20:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/bd5261436475733b/vertex-stock-flashes-a-surprise-entry-as-non-opioid-pain-drug-looms-investor-s-business-daily 2024-11-05T19:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/277478d77314a866/fda-approves-novel-combination-regimen-for-gi-cancers-the-asco-post 2024-11-05T19:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/48a453dcc2dccea3/alzheimer-s-drug-shows-slower-cognitive-decline-in-lower-tau-patients 2024-11-05T19:38:26+00:00 weekly 0.7 https://trial.medpath.com/news/b349f58dd73a69a2/genentech-to-present-blood-disorders-data-at-ash-markets-insider 2024-11-05T19:35:55+00:00 weekly 0.7 https://trial.medpath.com/news/050ac7b73fc03e76/ash24-novo-nordisk-takes-forma-s-sickle-cell-treatment-into-phase-3-endpoints-news 2024-11-05T19:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/8e47e44e29db416e/genomic-variations-associated-with-risk-and-protection-against-vincristine-induced-nature 2024-11-05T19:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/a711f3adc9f0b33c/organon-fda-extends-vtama-atopic-dermatitis-review-to-march-morningstar 2024-11-05T19:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/29e819fcd578a1ee/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T19:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/30baecaa1bf1119e/organon-co-filed-sec-form-8-k-regulation-fd-disclosure-financial-statements-and-exhibits 2024-11-05T18:58:49+00:00 weekly 0.7 https://trial.medpath.com/news/fc41a750c7450a90/fda-approves-envoy-medical-s-study-for-fully-implanted-cochlear-implant 2024-11-05T18:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/1bb207dcdffe780b/st-luke-s-surgeon-recognized-among-top-cited-scientists-saucon-source 2024-11-05T18:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/2b4bf95750dd2e1f/journey-medical-s-emrosi-secures-fda-nod-for-rosacea-treatment 2024-11-05T18:37:27+00:00 weekly 0.7 https://trial.medpath.com/news/df09541c965707b2/amc-health-receives-expanded-fda-clearance-for-advanced-virtual-care-and-risk 2024-11-05T18:27:55+00:00 weekly 0.7 https://trial.medpath.com/news/45ca800e85b14777/a-trial-of-vistusertib-and-paclitaxel-for-ovarian-cancer-that-has-come-back-octopus 2024-11-05T18:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/61acb29213ef1585/sickle-cell-patient-dies-in-beam-study-of-base-editing-therapy-biopharma-dive 2024-11-05T18:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/fdc5d5a04d57eb29/new-momentum-for-a-time-limited-conditional-approval-pathway-for-rare-disease-drugs 2024-11-05T18:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/41b95a31fa19cbb2/case-study-shows-striking-improvements-in-patient-with-metastatic-prostate-cancer 2024-11-05T18:11:07+00:00 weekly 0.7 https://trial.medpath.com/news/94c377c54e246ae1/phase-1-2-trial-of-del-brax-enrolling-new-possibly-pivotal-fshd-group-muscular-dystrophy-news 2024-11-05T18:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/ca455e415270f899/medtronic-recor-medical-score-renal-denervation-reimbursement-wins-massdevice 2024-11-05T18:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/4ed1b79b791520fb/medtronic-recor-win-cms-transitional-payment-coverage-for-renal-denervation-devices 2024-11-05T17:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/c2080a2666a08c65/fda-approves-journey-medical-s-emrosi-for-rosacea-drug-topics 2024-11-05T17:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/6e98d160fe440642/fda-accepts-ablas-for-prolia-r-xgeva-r-biosimilars-from-organon-and-teva-venable-llp 2024-11-05T17:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/a66ebf6f5efbbe66/iterum-therapeutics-receives-fda-ok-for-orlynvah-drug-store-news 2024-11-05T17:19:27+00:00 weekly 0.7 https://trial.medpath.com/news/c490144a7e453a85/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in 2024-11-05T17:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/09364643541607a4/sigmar1-activating-agent-blarcamesine-meets-pre-specified-efficacy-in-phase-2-3-trial-of 2024-11-05T17:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/0ff34741131214e2/fda-extends-review-period-for-zenocutuzumab-in-nrg1-pdac-nsclc 2024-11-05T17:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/50a25205c066d52d/dr-haggstrom-on-future-research-directions-in-egfr-and-alk-nsclc-onclive 2024-11-05T17:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/9eacccebda199ae2/lucky-gene-therapy-break-for-daily-wage-earner-s-son-times-of-india 2024-11-05T17:01:05+00:00 weekly 0.7 https://trial.medpath.com/news/bdff1f41231b75b6/clinical-trial-to-help-patients-undergoing-cancer-immunotherapy-yale-school-of-medicine 2024-11-05T16:57:28+00:00 weekly 0.7 https://trial.medpath.com/news/5a88b7f51e7ad40d/bolt-medical-announces-completion-of-restore-atk-and-restore-btk-pivotal-studies 2024-11-05T16:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/61cf1186c5df585f/h-c-wainwright-rytelo-off-to-a-strong-launch-assigns-buy-to-geron-shares-investing-com 2024-11-05T16:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/89a9bca13683fb7d/novo-nordisk-announces-positive-results-from-phase-3-essence-trial-of-semaglutide-2-4 2024-11-05T16:31:02+00:00 weekly 0.7 https://trial.medpath.com/news/488219b8f7d24b83/damona-pharmaceuticals-given-fda-approval-for-trial-of-dpx-101-for-brain-disorders 2024-11-05T16:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/b2f178727eb795e5/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T16:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/b6d754ee792bfc6f/fda-approves-journey-medical-s-rosacea-treatment-emrosi-pharmaceutical-technology 2024-11-05T16:20:54+00:00 weekly 0.7 https://trial.medpath.com/news/a2704e331c2a7d5f/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-cision-news 2024-11-05T16:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/db11a275e39b522f/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient 2024-11-05T16:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/5491fac05be62fa6/diamyd-medical-and-innodia-partner-for-type-1-diabetes-awareness-and-patient-placera 2024-11-05T16:04:52+00:00 weekly 0.7 https://trial.medpath.com/news/5260cdab2e0b9659/lyell-announces-presentation-of-initial-clinical-data-from-globenewswire 2024-11-05T15:49:57+00:00 weekly 0.7 https://trial.medpath.com/news/e4d92adee1a429bd/brief-overview-of-perseus-iskia-and-cassiopeia-clinical-trials-cancer-network 2024-11-05T15:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/57c3c1672e81a62d/native-hawaiians-pacific-islanders-found-to-be-underrepresented-in-clinical-trials 2024-11-05T15:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/50d58d2f1c869869/trials-update-our-q3-roundup-of-dementia-clinical-trials-news-being-patient 2024-11-05T15:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/c38f3bb580242f84/drap-launches-industry-e-reporting-system-to-monitor-drug-reaction-dental-news 2024-11-05T15:26:35+00:00 weekly 0.7 https://trial.medpath.com/news/cb8b0a4a7d64bfaa/pioneering-clinical-trial-to-treat-cancer-in-patients-with-fanconi-anaemia-uab 2024-11-05T15:23:41+00:00 weekly 0.7 https://trial.medpath.com/news/2bdd3b427c7a1c1d/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-markets-data 2024-11-05T15:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/ea96c807968ca2c2/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T15:05:50+00:00 weekly 0.7 https://trial.medpath.com/news/671ca8fbf0c9b0a1/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/000771db73f3a914/fda-approves-dfd-29-for-treatment-of-adults-with-rosacea-related-inflammatory-lesions 2024-11-05T14:52:01+00:00 weekly 0.7 https://trial.medpath.com/news/6b6a03e22af93634/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-for 2024-11-05T14:51:58+00:00 weekly 0.7 https://trial.medpath.com/news/b2a9b311be03dd85/maia-biotechnology-announces-late-breaking-abstract-of-thio-101-updates-selected-placera 2024-11-05T14:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/39aa8b0980abeff5/fda-extends-pdufa-date-for-zenocutuzumab-in-nrg1-nsclc-and-pancreatic-cancer 2024-11-05T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/3aee4cd08bcd50ed/lyell-announces-presentation-of-initial-clinical-data-from-the-phase-1-2-clinical-trial-of 2024-11-05T14:46:36+00:00 weekly 0.7 https://trial.medpath.com/news/6e75f93544a3d007/encouraging-data-revealed-for-schizophrenia-long-acting-injectables 2024-11-05T14:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/69fb67c25f69c328/roche-to-present-new-and-encouraging-long-term-follow-up-globenewswire 2024-11-05T14:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/b9c879b78d745530/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-morningstar 2024-11-05T14:23:55+00:00 weekly 0.7 https://trial.medpath.com/news/e0a619442c43e769/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-morningstar 2024-11-05T14:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/0884ff1a471e519a/genentech-to-present-new-and-encouraging-long-term-follow-up-data-across-broad 2024-11-05T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/57980c26c627dbc1/nurix-to-present-breakthrough-btk-degrader-data-at-ash-clinical-trial-results-revealed 2024-11-05T14:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/cee9da66c43b5164/eli-lilly-to-present-breakthrough-phase-3-results-for-jaypirca-at-ash-annual-meeting 2024-11-05T14:10:24+00:00 weekly 0.7 https://trial.medpath.com/news/1b76f0fa94e54d42/onclive-s-october-roundup-of-key-fda-approvals-in-oncology 2024-11-05T14:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/c6e8182b778c775c/ark-clinical-research-s-new-mobile-unit-pioneering-decentralized-clinical-yahoo-finance 2024-11-05T14:06:02+00:00 weekly 0.7 https://trial.medpath.com/news/9d29566bd65f6f72/nuvectis-pharma-inc-sec-10-q-report-tradingview 2024-11-05T14:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/6e02fea777d540fa/karyopharm-reports-third-quarter-2024-financial-results-and-highlights-recent-company-progress 2024-11-05T13:56:48+00:00 weekly 0.7 https://trial.medpath.com/news/78f8dfd39f0c113b/a-potent-intramolecular-nlrp3-glue-inhibitor-advancing-through-multiple-phase-ii-trials 2024-11-05T13:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/4b171c0f21d66c88/astrazeneca-s-fasenra-approved-by-ec-to-treat-rare-inflammatory-disease-egpa-pmlive 2024-11-05T13:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/6449d8bba37309f2/ema-accepts-marketing-authorization-application-for-biosimilar-to-simponi 2024-11-05T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/3bf3750e73504a15/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-product-in-pediatric-netherton 2024-11-05T13:17:46+00:00 weekly 0.7 https://trial.medpath.com/news/23f9a515f1bd05b5/imugene-says-bile-tract-cancer-patient-maintains-complete-response-in-mast-study-biotech 2024-11-05T13:13:56+00:00 weekly 0.7 https://trial.medpath.com/news/c2994b675265e396/quoin-pharmaceuticals-initiates-clinical-testing-of-lead-globenewswire 2024-11-05T13:13:44+00:00 weekly 0.7 https://trial.medpath.com/news/2652aa6c93cfb13f/ankyra-therapeutics-announces-first-visceral-tumor-patient-dosed-in-phase-1-anchor 2024-11-05T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/e5c631fd78b7b779/insignis-therapeutics-receives-positive-fda-feedback-on-in-001-clinical-program-for 2024-11-05T13:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/86c761869cbef86a/quoin-s-qrx003-shows-promise-in-pediatric-netherton-syndrome-trial-expansion-stock-titan 2024-11-05T13:05:30+00:00 weekly 0.7 https://trial.medpath.com/news/7992a5818281f0e1/new-coalition-launches-to-transform-cancer-supportive-care-delivery-nationwide 2024-11-05T13:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/e6024bb91d38cccb/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-yahoo-finance 2024-11-05T12:40:39+00:00 weekly 0.7 https://trial.medpath.com/news/d4deeff20145b44d/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-05T12:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/f834288e4b70d617/intra-cellular-therapies-announces-positive-topline-results-in-phase-3-trial-evaluating 2024-11-05T12:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/5e882c80b5959641/ac-immune-reports-third-quarter-2024-financial-results-and-provides-a-corporate-update 2024-11-05T12:37:22+00:00 weekly 0.7 https://trial.medpath.com/news/241d997e0f4e0b11/delta-fly-pharma-inc-update-for-expanded-phase-i-study-of-dfp-14927-afp-com 2024-11-05T12:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/b7a14c4f8eb31c30/zyversa-s-breakthrough-new-data-shows-promise-for-type-2-diabetes-prevention-zvsa-stock 2024-11-05T12:33:09+00:00 weekly 0.7 https://trial.medpath.com/news/4aa4376ae2ba00e1/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-biospace 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/806efe296d84f357/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-05T12:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/d8334a1b6170cb3b/angitia-biopharmaceuticals-announces-dosing-of-first-patient-in-phase-2-clinical-trial-of 2024-11-05T12:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/8f13abed78eed4a8/national-hiv-drug-resistance-surveillance-among-adults-with-viral-non-suppression-in-south-africa 2024-11-05T12:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/f17a3994fcb44e7a/germany-announces-2-further-planned-adult-use-cannabis-trials-but-legislation-not-yet 2024-11-05T12:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/a33d51f5d54f8d15/ema-accepts-alvotech-and-advanz-pharma-s-avt05-maa-pharmaceutical-technology 2024-11-05T12:14:54+00:00 weekly 0.7 https://trial.medpath.com/news/badb637d7033254f/itci-s-caplyta-shows-breakthrough-63-reduction-in-schizophrenia-relapse-risk 2024-11-05T12:13:51+00:00 weekly 0.7 https://trial.medpath.com/news/eb6349fd80f35333/astrazeneca-bolsters-obesity-pipeline-with-promising-early-data-for-candidates-biospace 2024-11-05T12:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/2615861b85fd6a63/s93-phase-3-notus-trial-dupilumab-efficacy-and-safety-in-patients-with-moderate-to-severe 2024-11-05T11:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/be8cac10a93bb36b/how-3d-printing-could-transform-solid-oral-dosage-forms-the-medicine-maker 2024-11-05T11:34:27+00:00 weekly 0.7 https://trial.medpath.com/news/4a0beba47f191d97/how-hybrid-models-and-tech-are-shaping-the-future-of-clinical-research 2024-11-05T11:29:34+00:00 weekly 0.7 https://trial.medpath.com/news/5db550ec932924c1/how-this-clinical-trial-could-help-alzheimer-s-patients-wptv 2024-11-05T11:20:46+00:00 weekly 0.7 https://trial.medpath.com/news/aba5fc1af18f2b27/zymeworks-announces-first-patient-dosed-in-phase-1-clinical-trial-evaluating-zw191-in 2024-11-05T11:12:58+00:00 weekly 0.7 https://trial.medpath.com/news/1b1aebc7379a905c/why-treatments-can-fail-folks-with-wet-macular-degeneration-and-what-might-really-work 2024-11-05T11:11:26+00:00 weekly 0.7 https://trial.medpath.com/news/7083a1f78cd22bc5/press-release-service-vertex-reports-third-quarter-2024-financial-results 2024-11-05T11:03:49+00:00 weekly 0.7 https://trial.medpath.com/news/fa947903c466ed41/the-reliever-reliance-test-evaluating-a-new-tool-to-address-saba-over-reliance-nature 2024-11-05T10:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/7209413b49962bd8/interleukin-6-receptor-antibodies-tocilizumab-in-acute-myocardial-infarction-with-trials 2024-11-05T10:45:57+00:00 weekly 0.7 https://trial.medpath.com/news/d89896286351425c/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T10:29:09+00:00 weekly 0.7 https://trial.medpath.com/news/f01ef839331bce68/how-this-clinical-trial-could-help-alzheimer-s-patients-wflx 2024-11-05T10:18:30+00:00 weekly 0.7 https://trial.medpath.com/news/bc6e0472eb89cc0c/breakthrough-prenatal-therapy-saves-children-with-congenital-vascular-malformations 2024-11-05T10:13:33+00:00 weekly 0.7 https://trial.medpath.com/news/dfddc806e8d29393/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-05T10:07:17+00:00 weekly 0.7 https://trial.medpath.com/news/fc631ee547bb420b/leading-cancer-centers-form-ai-alliance-with-40m-tech-industry-backing-to-revolutionize-cancer-research 2024-11-05T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/9ef420d4d6c9dbf7/alvotech-and-teva-announce-fda-approval-of-additional-presentation-for-ustekinumab-biosimilar 2024-11-05T09:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/9f510bcd889fc8ce/janus-kinase-jak-inhibitors-pipeline-assessment-2024-ema-openpr-com 2024-11-05T09:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/1f57d271a7fd7b11/photocure-partner-asieris-announces-marketing-approval-by-the-national-medical-products 2024-11-05T09:44:58+00:00 weekly 0.7 https://trial.medpath.com/news/8bef94f6cc8c8b99/qyuns-therapeutics-drug-approval-boosts-market-presence-tipranks-com 2024-11-05T09:43:18+00:00 weekly 0.7 https://trial.medpath.com/news/e1ee0e897b7b3df4/european-medicines-agency-confirms-acceptance-of-marketing-authorization-pipelinereview 2024-11-05T09:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/6f855421e9284ba7/november-5-2024-study-snapshot-and-updated-ethics-documentation-available-for-moms 2024-11-05T09:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/f71399bfa923cb19/eligibility-and-endpoints-for-clinical-trials-in-trimodality-therapy-for-bladder-cancer 2024-11-05T09:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/7a779782c1f48dc8/oak-hill-bio-and-chiesi-s-ohb-607-trial-enrols-first-european-subject-for-bpd-prevention 2024-11-05T09:00:35+00:00 weekly 0.7 https://trial.medpath.com/news/ff39bac91b9b1a79/who-launches-new-clinical-trials-guidance-what-do-i-need-to-know 2024-11-05T08:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/f0c32c64e2b57ebc/efficacy-and-safety-of-jmt103-in-patients-with-unresectable-or-surgically-challenging-giant-nature 2024-11-05T07:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/34ae85d28f727a4f/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application 2024-11-05T07:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/b236f752c8f7d331/abbott-s-freestyle-libre-cgm-systems-receive-first-ever-approval-for-use-during-medical-imaging-as-semaglutide-supply-stabilizes 2024-11-05T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/4d7821c730982fa1/hookipa-pharma-s-swot-analysis-stock-s-potential-in-immunotherapy-market 2024-11-05T06:41:57+00:00 weekly 0.7 https://trial.medpath.com/news/cbdf71793fd9a8e9/uk-government-partners-with-oxford-nanopore-to-launch-nhs-wide-pathogen-surveillance-system 2024-11-05T06:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/1a9badf3a0f40494/medical-moment-new-fda-approved-implants-for-shoulder-replacements-wndu 2024-11-05T06:15:40+00:00 weekly 0.7 https://trial.medpath.com/news/c73379f9c59f533a/pembrolizumab-combo-shows-promising-results-in-high-risk-cervical-cancer 2024-11-05T06:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/5abd11817a0051e2/study-reveals-gap-in-masld-related-liver-cancer-screening-26-of-non-cirrhotic-cases-show-low-fib-4-scores 2024-11-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e354c78107fa2f6a/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-yahoo-finance 2024-11-05T05:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/e4d46e9f4d1b2051/first-rounds-of-late-breaking-clinical-trial-results-announced-at-viva24-pr-newswire 2024-11-05T05:51:42+00:00 weekly 0.7 https://trial.medpath.com/news/48e692574478a41b/ncats-award-will-support-multi-site-study-to-evaluate-remote-trials-university-at-buffalo 2024-11-05T05:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/973d5cf6e5fbf4dd/biocity-presents-late-breaking-clinical-trial-results-with-sc0062-for-iga-nephropathy-at-asn 2024-11-05T05:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/90adabdb8c3150f2/northwest-ehealth-nweh-announces-a-pilot-to-test-a-new-model-for-finding-and-recruiting 2024-11-05T05:14:32+00:00 weekly 0.7 https://trial.medpath.com/news/c0790fe34682c424/iron-chelator-deferiprone-shows-adverse-effects-in-early-alzheimer-s-disease-trial 2024-11-05T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/7c38d804a93b9a53/world-s-first-drug-to-regrow-teeth-is-now-in-clinical-trials-the-brighter-side-of-news 2024-11-05T04:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/30e2121cf2cab078/lumithera-obtains-fda-authorization-of-valeda-treatment-for-dry-amd-patients-to-improve-vision 2024-11-05T04:35:01+00:00 weekly 0.7 https://trial.medpath.com/news/14474f717a6ab821/verona-pharma-reports-strong-q3-launch-for-copd-drug-tipranks-com 2024-11-05T04:20:48+00:00 weekly 0.7 https://trial.medpath.com/news/4668a1346c7a6f44/cytodyn-inc-announces-fda-clearance-of-its-phase-ii-oncology-trial-marketscreener 2024-11-05T03:26:48+00:00 weekly 0.7 https://trial.medpath.com/news/a6699917da8082d8/ribomic-announces-positive-interim-results-from-phase-iia-trial-of-umedaptanib-pegol-in-achondroplasia 2024-11-05T03:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/46fd008f819e5320/vertex-pharmaceuticals-vrtx-q3-2024-earnings-call-transcript-the-globe-and-mail 2024-11-05T02:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/ea16742a6438f838/breakthrough-or-bust-big-pharma-s-surprising-moves-jomfruland-net 2024-11-05T02:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/00239693c3401934/xencor-doses-first-subject-in-phase-1-2-study-of-xmab-r-942-in-development-for-patients 2024-11-05T02:14:45+00:00 weekly 0.7 https://trial.medpath.com/news/eadc15532ba872fe/sana-biotechnology-pivots-to-autoimmune-focus-announces-layoffs-and-pipeline-restructuring 2024-11-05T01:40:00+00:00 weekly 0.7 https://trial.medpath.com/news/138ce8d76900cade/recce-says-patient-dosing-in-phase-2-clinical-trial-advances-to-final-stages-biotech 2024-11-05T01:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/1d4c6e4f5c3e3c8c/cervomed-announces-key-takeaways-from-oral-presentations-at-the-17th-clinical-trials-on 2024-11-05T01:26:31+00:00 weekly 0.7 https://trial.medpath.com/news/d2a7b690ed694e2b/niagara-trial-shows-durvalumab-plus-chemotherapy-improves-survival-in-muscle 2024-11-05T01:26:12+00:00 weekly 0.7 https://trial.medpath.com/news/67495a9107fa5ebd/nationwide-epilepsy-clinical-trial-investigates-potential-new-treatment-the-rochelle-news-leader 2024-11-05T01:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/18ee7657846dcdbf/merus-receives-fda-extension-of-pdufa-for-zenocutuzumab 2024-11-05T01:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/60fdcbf938cbf47f/quantatm-dialysis-system-receives-fda-clearance-for-home-hemodialysis 2024-11-05T00:52:34+00:00 weekly 0.7 https://trial.medpath.com/news/fa27b8ba8926fd81/5-year-follow-up-of-the-phase-2-optic-study-in-patients-with-chronic-phase-chronic-myeloid-leukemia 2024-11-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/e142ab32b1cd7862/breakthrough-in-type-1-diabetes-reprogramming-fat-cells-to-restore-insulin-production 2024-11-04T23:59:55+00:00 weekly 0.7 https://trial.medpath.com/news/a42a49d4783a2b7e/guess-which-asx-300-stock-is-jumping-11-on-big-news-motley-fool 2024-11-04T23:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/c79af5bf5fbd7d28/neuraxis-wins-expanded-fda-clearance-for-non-implanted-neurostim-for-pain-relief 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/e4e57f407fc3915c/fda-approves-ide-for-akura-medical-s-thrombectomy-system-massdevice 2024-11-04T23:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/b96bc9b4ecea1ac4/teva-shares-positive-phase-iii-data-of-schizophrenia-injectable-tev-749 2024-11-04T23:23:49+00:00 weekly 0.7 https://trial.medpath.com/news/ffa83c4325004027/unity-biotechnology-inc-sec-10-q-report-tradingview 2024-11-04T23:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/7a622ebeeb6d3480/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic-treatment-of-hae 2024-11-04T23:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/0795988dcc6349ba/dupilumab-reduces-itch-in-chronic-spontaneous-urticaria-in-phase-3-data-hcplive 2024-11-04T23:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/76b01b69e2bb957c/first-of-a-kind-case-study-shows-remarkable-improvements-for-prostate-cancer-patient 2024-11-04T23:01:58+00:00 weekly 0.7 https://trial.medpath.com/news/e73ff126b5fab190/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-longview-news-journal 2024-11-04T22:54:16+00:00 weekly 0.7 https://trial.medpath.com/news/5ce14a4abb1be424/another-arrow-to-the-quiver-for-physicians-fda-approves-emrosi-for-rosacea-healio 2024-11-04T22:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/e9dccd638862a273/adverum-biotechnologies-inc-sec-10-q-report-tradingview 2024-11-04T22:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/9b0628472d2e3b62/simbiosys-achieves-second-fda-clearance-for-tumorsighttm-viz-and-introduces-pr-newswire 2024-11-04T22:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/f36f1ecad0508a24/precision-biosciences-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T22:02:40+00:00 weekly 0.7 https://trial.medpath.com/news/f16cdbfeb770c16d/maia-biotechnology-director-steven-chaouki-buys-55553-in-shares-investing-com 2024-11-04T22:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/4d1d255f7f98fbf0/maia-biotechnology-director-luput-acquires-shares-worth-55553-investing-com 2024-11-04T21:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/21937ff8e0f2ca9b/aquestive-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-04T21:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/d938ea6be6ee8ce2/unity-biotechnology-inc-reports-third-quarter-2024-globenewswire 2024-11-04T21:39:08+00:00 weekly 0.7 https://trial.medpath.com/news/88bf2110afbc192f/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:38:00+00:00 weekly 0.7 https://trial.medpath.com/news/71c8623c21e0e2ef/unity-biotechnology-inc-reports-third-quarter-2024-financial-results-and-business-updates 2024-11-04T21:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/d84315b6b70a7aa0/neuropace-announces-fda-submission-of-three-year-data-from-post-approval-study-of 2024-11-04T21:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/eda1059298d33043/fda-approves-new-option-for-rosacea-medpage-today 2024-11-04T21:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/ef432cae8b77ab2f/fda-breakthrough-therapy-designation-shows-38-7-approval-rate-with-317-products-receiving-market-authorization 2024-11-04T21:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/fbc1bf3a847844a6/neuropace-announces-fda-submission-of-three-year-data-from-globenewswire 2024-11-04T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/af43fa51bfcb41ff/novel-gene-therapy-for-neovascular-age-related-macular-degeneration-medpage-today 2024-11-04T21:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/387ca7e57ac2acda/lsd-the-bad-and-potentially-good-sides-psychology-today 2024-11-04T20:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/97abc241225154e1/letter-warns-clinicians-of-severe-infections-with-pralsetinib-for-nsclc 2024-11-04T20:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/106bfd4f96ca671d/new-found-gold-pulls-high-grade-gold-out-of-queensway-project-in-newfoundland 2024-11-04T20:28:42+00:00 weekly 0.7 https://trial.medpath.com/news/2a9a696341744058/phase-3-trial-of-tavneos-enrolling-children-ages-6-17-with-aav-anca-vasculitis-news 2024-11-04T20:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/faf5e4a5dc7096a1/a-crazy-idea-for-treating-autoimmune-diseases-might-actually-work-the-atlantic 2024-11-04T20:13:01+00:00 weekly 0.7 https://trial.medpath.com/news/226994f024d5f371/disc-teases-potential-nda-for-rare-skin-disorder-drug-clinical-trials-arena 2024-11-04T20:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/1581708d512c774e/philips-enrolls-first-patient-in-u-s-clinical-trial-for-globenewswire 2024-11-04T19:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/a53ec5d0fe5e56f3/shockwave-medical-s-javelin-ivl-catheter-meets-primary-trial-endpoints-massdevice 2024-11-04T19:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/a04f981c1b604fd4/fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-its-magnitude-r-drug 2024-11-04T19:44:48+00:00 weekly 0.7 https://trial.medpath.com/news/dc2b26d7f8ecf1d5/us-fda-approves-ide-application-for-katana-thrombectomy-system-venous-news 2024-11-04T19:40:52+00:00 weekly 0.7 https://trial.medpath.com/news/219c2aab00ad8a75/roflumilast-reduces-disease-impact-of-atopic-dermatitis-hcplive 2024-11-04T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/508e22a7807ea511/cytodyn-announces-fda-clearance-of-its-phase-ii-oncology-trial-globenewswire 2024-11-04T19:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/bf7bf76e3f3501a8/enhancing-diversity-and-accessibility-in-clinical-trials-for-alzheimer-disease-neurologylive 2024-11-04T19:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/88658ac0f7f97bc8/the-state-of-the-art-of-n-of-1-therapies-and-the-irdirc-n-of-1-development-roadmap 2024-11-04T18:58:12+00:00 weekly 0.7 https://trial.medpath.com/news/08b763bfe6b169ac/unexpected-immunotherapy-success-in-rare-pancreatic-cancer-news-medical 2024-11-04T18:40:10+00:00 weekly 0.7 https://trial.medpath.com/news/7276540695b18068/clinical-trial-forges-new-standard-of-care-for-advanced-hodgkin-lymphoma-inventum 2024-11-04T18:23:21+00:00 weekly 0.7 https://trial.medpath.com/news/34694cb6a9d44d7b/new-funding-drives-a-slew-of-breast-cancer-studies-fred-hutchinson-cancer-center 2024-11-04T18:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/d3ad7dabcb1a44ef/semaglutide-2-4-mg-shows-superior-improvement-in-liver-fibrosis-mash-resolution-in 2024-11-04T18:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/5ebdf5e8ffc7321b/journey-medical-corporation-announces-u-s-fda-approval-of-emrositm-minocycline 2024-11-04T18:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/37bc3f5780276ac0/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase 2024-11-04T18:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/f10dc48990185260/fda-accepts-donidalorsen-nda-for-prophylactic-hereditary-angioedema 2024-11-04T18:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/fbcf7b073028d51c/urticaria-clinical-trial-pipeline-accelerates-20-leading-globenewswire 2024-11-04T18:03:31+00:00 weekly 0.7 https://trial.medpath.com/news/336e9ce819700ab6/clinical-validation-of-an-ai-based-pathology-tool-for-scoring-of-metabolic-dysfunction 2024-11-04T18:00:49+00:00 weekly 0.7 https://trial.medpath.com/news/46e933710b41f61f/deferiprone-in-alzheimer-disease-a-randomized-clinical-trial-jama-network 2024-11-04T17:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/93dcb924d00c306e/novo-s-semaglutide-scores-in-liver-fibrosis-and-mash-trial-inside-precision-medicine 2024-11-04T17:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/adf9aa204e619807/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-pivotal-tool-in-roche-s-phase-iii 2024-11-04T17:52:53+00:00 weekly 0.7 https://trial.medpath.com/news/05d37b4b68507338/predicinecaretm-liquid-biopsy-assay-featured-in-nejm-as-globenewswire 2024-11-04T17:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/8d6494598f51684f/100-biomarker-lab-test-for-alzheimer-s-disease-developed-by-team-at-university-of-pittsburgh 2024-11-04T17:43:20+00:00 weekly 0.7 https://trial.medpath.com/news/95de54d4a4fcd1d5/phaxiam-fda-green-light-for-phase-ii-study-marketscreener 2024-11-04T17:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/0fe1bb3c7ceafb77/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T17:39:03+00:00 weekly 0.7 https://trial.medpath.com/news/2be0282fcb922f26/spectral-medical-provides-october-tigris-trial-update-globenewswire 2024-11-04T17:34:15+00:00 weekly 0.7 https://trial.medpath.com/news/063387d6dbf424e0/fda-grants-clearance-for-study-of-envoy-medical-s-cochlear-implant-yahoo 2024-11-04T17:24:42+00:00 weekly 0.7 https://trial.medpath.com/news/51cbbbb94b7fb4f6/teva-s-long-lasting-schizophrenia-injectable-shines-in-phase-iii-clinical-trials-arena 2024-11-04T17:24:08+00:00 weekly 0.7 https://trial.medpath.com/news/6fb9d37fe0cd8bc4/sagimet-planning-phase-3-trials-of-denifanstat-in-mash-masld-liver-disease-news 2024-11-04T17:20:51+00:00 weekly 0.7 https://trial.medpath.com/news/e7c3e38e535e0de2/ela026-receives-orphan-drug-designation-to-treat-hemophagocytic-lymphohistiocytosis 2024-11-04T17:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/91eec3226123462b/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/cc3a92bfb77c5735/phaxiam-therapeutics-receives-fda-clearance-to-initiate-phase-ii-gloria-study-in-the-u-s 2024-11-04T17:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/3b21914118391143/r3-vascular-wins-fda-ide-for-drug-eluting-scaffold-massdevice 2024-11-04T16:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/c9cfa53f4cb041b9/alzheimer-s-drug-hailed-as-major-breakthrough-could-actually-triple-risk-of-dying-ucl-news 2024-11-04T16:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/7e3ceca523223d4b/polypid-shares-rise-on-strong-phase-3-prospects-gets-buy-rating-investing-com 2024-11-04T16:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/982c81dea2e75b06/immunotherapy-combination-may-demonstrate-benefit-in-patients-with-cutaneous-melanoma 2024-11-04T16:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/6326aa4839754067/results-of-elevatim-show-improvement-in-diabetic-macular-edema-with-vabysmo-for 2024-11-04T16:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/23a4e157a22a400a/viking-therapeutics-presents-positive-data-from-vk2735-for-reducing-body-weight 2024-11-04T16:23:57+00:00 weekly 0.7 https://trial.medpath.com/news/eb13f2b784ef3b67/valemetostat-in-relapsed-or-refractory-peripheral-t-cell-lymphoma-the-asco-post 2024-11-04T16:20:17+00:00 weekly 0.7 https://trial.medpath.com/news/0f1c817deb1d5208/neoadjuvant-shr-a1811-plus-pyrotinib-shows-preliminary-efficacy-safety-in-her2-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/6b78e0e5af708118/lasofoxifene-suppresses-ki-67-expression-in-hr-her2-early-stage-breast-cancer 2024-11-04T16:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/ba18c37c332da3d0/bxq-350-is-well-tolerated-shows-clinical-activity-in-advanced-solid-tumors-onclive 2024-11-04T16:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/5b7ee90f5c0ec458/sutro-biopharma-begins-trial-of-acute-myeloid-leukaemia-treatment-in-children 2024-11-04T16:11:32+00:00 weekly 0.7 https://trial.medpath.com/news/d2f13ed6560d042d/key-fda-decisions-made-in-2024-news-medical 2024-11-04T16:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/6b22c3f75689d66b/fda-clears-quanta-home-hemodialysis-system-massdevice 2024-11-04T16:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/2fcf45393947b2a9/radiprodil-in-tsc-and-fcd-targeting-seizures-through-nmda-modulation-neurologylive 2024-11-04T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/ded861d801c344bb/cilta-cel-may-outperform-standard-care-for-relapsed-refractory-myeloma 2024-11-04T16:06:50+00:00 weekly 0.7 https://trial.medpath.com/news/5a91d4b60284ebf6/first-patients-dosed-in-new-phase-3-trials-of-dato-dxd-in-nsclc-targeted-oncology 2024-11-04T16:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/7970f87cb455cd8d/clofutriben-receives-fda-orphan-drug-designation-to-treat-endogenous-cushing-syndrome 2024-11-04T15:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/7a44d29ea71fc127/ventus-therapeutics-announces-positive-phase-1-trial-results-for-investigational-drug 2024-11-04T15:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/e310d1c2d4928c12/raymond-james-increases-disc-medicine-shares-to-strong-buy-on-new-drug-investing-com 2024-11-04T15:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/ffecdbce9b346841/viking-therapeutics-weight-loss-pill-outperforms-ozempic-marker-novo-nordisk-s-quartz 2024-11-04T15:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/574578b8eeb14212/us-fda-grants-r3-vascular-ide-approval-for-elite-btk-pivotal-trial-of-magnitude-drug 2024-11-04T15:39:52+00:00 weekly 0.7 https://trial.medpath.com/news/bfdd0cf5f3f420ed/new-guselkumab-data-indicate-robust-effectiveness-in-crohn-disease-plaque-psoriasis 2024-11-04T15:34:33+00:00 weekly 0.7 https://trial.medpath.com/news/c62499926002f9c4/fda-approves-journey-medical-s-dfd-29-for-rosacea-dermatology-times 2024-11-04T15:24:58+00:00 weekly 0.7 https://trial.medpath.com/news/32a3e79923845a92/fda-lifts-clinical-holds-placed-on-3-car-t-cell-therapy-trials-targeted-oncology 2024-11-04T15:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/e5b9d78ca114a8ed/fda-grants-approval-to-commence-trial-of-r3-vascular-s-scaffold-medical-device-network 2024-11-04T15:16:37+00:00 weekly 0.7 https://trial.medpath.com/news/3d866a71ad3ff71e/implant-could-prevent-opioid-overdose-deaths-news-center 2024-11-04T15:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/8b2ab4c78f4ca962/saint-itbs-protocol-shows-promise-for-bipolar-i-depression-psychiatric-times 2024-11-04T15:04:23+00:00 weekly 0.7 https://trial.medpath.com/news/bdd49c7f5fb3499e/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/64d196d7b24ee3a8/parkinson-disease-therapy-current-strategies-and-future-research-priorities-nature 2024-11-04T14:57:53+00:00 weekly 0.7 https://trial.medpath.com/news/6b5fa91662dd4f74/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:56:27+00:00 weekly 0.7 https://trial.medpath.com/news/012b0e983150f7ef/ionis-announces-fda-acceptance-of-new-drug-application-for-donidalorsen-for-prophylactic 2024-11-04T14:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/c1dd7daa2886d866/small-molecules-sustaining-big-pharma-a-look-at-some-recent-headlines-the-medicine-maker 2024-11-04T14:47:26+00:00 weekly 0.7 https://trial.medpath.com/news/02de0627c1699e43/akura-medical-secures-fda-approval-for-us-pivotal-trial-in-pulmonary 2024-11-04T14:41:28+00:00 weekly 0.7 https://trial.medpath.com/news/003e4efcdbc6324c/philips-enrolls-first-patient-in-u-s-clinical-trial-for-innovative-integrated-single-device-to-treat 2024-11-04T14:36:44+00:00 weekly 0.7 https://trial.medpath.com/news/3cc82aa5ab6e9b36/dosing-begins-in-early-clinical-trial-of-lucid-ms-to-protect-myelin-sheath 2024-11-04T14:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/3f294738282a71a1/viking-therapeutics-shines-with-promising-results-for-new-obesity-drug-finimize 2024-11-04T14:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/0dd92ba99db88337/prehabilitative-rehabilitative-exercise-nutrition-and-psychological-support-for-bladder-cancer 2024-11-04T14:27:11+00:00 weekly 0.7 https://trial.medpath.com/news/d6f3adf065165791/neuraxis-receives-new-fda-510-k-clearance-for-ib-stim-expanding-its-addressable-market 2024-11-04T14:25:27+00:00 weekly 0.7